[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f2U7nKLfDareFDszGT9T_gSFCmXDWDJjdEHlyvtqD8gs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Sheba Medical Center",[4],672,false,40,35,2794504,19,481,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Schizophrenia",14,{"name":18,"count":19},"Coronary Artery Disease",11,{"name":21,"count":22},"Healthy",9,{"name":24,"count":22},"Multiple Sclerosis",{"name":26,"count":27},"Stroke",8,{"name":29,"count":30},"Major Depressive Disorder",7,{"name":32,"count":30},"Pregnancy",{"name":34,"count":35},"Cerebral Palsy",6,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04519151","Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer","2023-11","Pembrolizumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05243212","Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma","2024-09-01","CAR-BCMA",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06087757","Clemastine Treatment in Individuals With Williams Syndrome","2026-05","Open Label Clemastine with a blinded randomize withdrawal",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06907498","Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults","2026-06","Paromomycin",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07399756","Mitochondrial Function After Ketamine","2026-09","S (+) Ketamine",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05000710","Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy","2026-12","Durvalumab",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04836910","Microbiome and Polycystic Ovaries","2027-03-30","Oral contraceptive pills",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07308964","Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease","2028-01","Teprotumumab Injection [Tepezza]",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07401524","Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage","2028-03-01","Carbetocin",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05909618","Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases","2028-07-30","Crizanlizumab-Tmca 10 MG\u002F1 ML Intravenous Solution [ADAKVEO]",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,130,148,172,196,252,275,293,316,342,371,389,414,432,454,481,514,535,553,572,616,665,702,738,775,805,830,856,880,902,928,946,969,992,1018,1036,1059,1086,1104,1130,1148,1176,1194,1212,1230,1255,1280,1298,1325,1343,1369,1387,1412,1436,1459,1477,1499,1523,1545,1567,1585,1610,1628,1651,1675,1702,1720,1738,1763,1781,1807,1825,1852,1876,1894,1912,1935,1953,1971,1994,2031,2056,2083,2106,2129,2152,2177,2201,2224,2249,2274,2297,2315,2333,2356,2378,2396,2422,2446,2467,2490,2508,2530,2553,2577,2600,2627,2645,2668,2694,2712,2737,2791,2827,2854,2883,2905,2933,2955,2973,2998,3016,3040,3064,3092,3115,3138,3162,3187,3210,3232,3261,3279,3297,3320,3344,3362,3386,3404,3429,3452,3476,3500,3524,3546,3573,3591,3609,3631,3654,3677,3695,3718,3736,3764,3782,3800,3825,3850,3876,3901,3926,3949,3974,3992,4049,4081,4107,4136,4169,4195,4213,4242,4268,4291,4316,4340,4363,4388,4406,4429,4454,4478,4505,4523,4541,4565,4590,4615,4633,4655,4679,4704,4722,4746,4769,4792,4816,4834,4857,4875,4897,4919,4943,4965,4989,5007,5029,5054,5072,5094,5120,5138,5161,5183,5209,5233,5251,5275,5299,5322,5340,5362,5383,5405,5427,5449,5473,5496,5522],{"intervention":96,"totalTrials":97,"cells":98},"Intravenous Ampicillin followed by Oral Amoxicillin",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":128},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":126},"NCT07183462","Azithromycin and Ampicillin for Late PPROM","RECRUITING",[92],"2029-06-30","2029-07-31","2025-09-10",311,[120,121,122,123,124,125],"Pregnancy Complications, Infectious","Premature Birth","Neonatal Diseases and Abnormalities","Antibiotic Prophylaxis","Latency Period","Prematurity",[96,127],"Ampicillin\u002FAmoxicillin plus single-dose PO Azithromycin",{"trials":129,"activeCount":101},[],{"intervention":127,"totalTrials":97,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":138,"PHASE4":140,"NA":146},{"trials":133,"activeCount":101},[],{"trials":135,"activeCount":101},[],{"trials":137,"activeCount":101},[],{"trials":139,"activeCount":101},[],{"trials":141,"activeCount":97,"soonestReadout":115},[142],{"nctId":111,"briefTitle":112,"status":113,"phases":143,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":144,"interventions":145},[92],[120,121,122,123,124,125],[96,127],{"trials":147,"activeCount":101},[],{"intervention":81,"totalTrials":97,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":158,"NA":170},{"trials":151,"activeCount":101},[],{"trials":153,"activeCount":101},[],{"trials":155,"activeCount":101},[],{"trials":157,"activeCount":101},[],{"trials":159,"activeCount":97,"soonestReadout":80},[160],{"nctId":78,"briefTitle":79,"status":113,"phases":161,"primaryCompletion":80,"completion":162,"start":163,"enrollment":164,"conditions":165,"interventions":168},[92],"2028-12-01","2026-05-05",120,[166,167],"Postpartum Hemorrhage","Twin Pregnancy",[81,169],"Oxytocin",{"trials":171,"activeCount":101},[],{"intervention":76,"totalTrials":97,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":194},{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"trials":179,"activeCount":101},[],{"trials":181,"activeCount":101},[],{"trials":183,"activeCount":97,"soonestReadout":75},[184],{"nctId":73,"briefTitle":74,"status":185,"phases":186,"primaryCompletion":75,"completion":187,"start":188,"enrollment":8,"conditions":189,"interventions":193},"NOT_YET_RECRUITING",[92],"2028-05","2026-01",[190,191,192],"Thyroid Eye Disease","Thyroid Eye Disease, TED","Thyroid Eye Disease (TED)",[76],{"trials":195,"activeCount":101},[],{"intervention":169,"totalTrials":197,"cells":198},4,{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":220,"PHASE4":233,"NA":239},{"trials":200,"activeCount":101},[],{"trials":202,"activeCount":101},[],{"trials":204,"activeCount":101},[205],{"nctId":206,"briefTitle":207,"status":208,"phases":209,"primaryCompletion":210,"completion":211,"start":212,"enrollment":213,"conditions":214,"interventions":219},"NCT01598623","Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients","UNKNOWN",[90],"2014-02","2014-09","2012-05",48,[215,216,217,218],"Oxytocin + Non Specific Counselling","Oxytocin + Social Skills Training","Placebo + Non Specific Counselling","Placebo + Social Skills Training",[169],{"trials":221,"activeCount":101},[222],{"nctId":223,"briefTitle":224,"status":208,"phases":225,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},"NCT03001635","Role of Oxytocin in Myocardial Infarction",[90,91],"2018-12","2017-01",52,[230],"Myocardial Infarction",[169,232],"Placebos",{"trials":234,"activeCount":97,"soonestReadout":80},[235],{"nctId":78,"briefTitle":79,"status":113,"phases":236,"primaryCompletion":80,"completion":162,"start":163,"enrollment":164,"conditions":237,"interventions":238},[92],[166,167],[81,169],{"trials":240,"activeCount":101},[241],{"nctId":242,"briefTitle":243,"status":208,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":251},"NCT01039766","The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)",[93],"2011-01","2011-06","2010-02",24,[250],"Stress Disorders, Post-Traumatic",[169],{"intervention":66,"totalTrials":97,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":269,"PHASE4":271,"NA":273},{"trials":255,"activeCount":101},[],{"trials":257,"activeCount":101},[],{"trials":259,"activeCount":97,"soonestReadout":65},[260],{"nctId":63,"briefTitle":64,"status":261,"phases":262,"primaryCompletion":65,"completion":65,"start":263,"enrollment":264,"conditions":265,"interventions":267},"ACTIVE_NOT_RECRUITING",[90],"2021-12-09",29,[266],"Metastatic or Locally Advanced NSCLC",[66,268],"Tremelimumab",{"trials":270,"activeCount":101},[],{"trials":272,"activeCount":101},[],{"trials":274,"activeCount":101},[],{"intervention":268,"totalTrials":97,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":287,"PHASE4":289,"NA":291},{"trials":278,"activeCount":101},[],{"trials":280,"activeCount":101},[],{"trials":282,"activeCount":97,"soonestReadout":65},[283],{"nctId":63,"briefTitle":64,"status":261,"phases":284,"primaryCompletion":65,"completion":65,"start":263,"enrollment":264,"conditions":285,"interventions":286},[90],[266],[66,268],{"trials":288,"activeCount":101},[],{"trials":290,"activeCount":101},[],{"trials":292,"activeCount":101},[],{"intervention":46,"totalTrials":97,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":296,"activeCount":101},[],{"trials":298,"activeCount":101},[],{"trials":300,"activeCount":97,"soonestReadout":45},[301],{"nctId":43,"briefTitle":44,"status":113,"phases":302,"primaryCompletion":45,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":309},[89,90],"2028-09-01","2021-09-19",75,[307,308],"Multiple Myeloma","Relapse Multiple Myeloma",[46],{"trials":311,"activeCount":101},[],{"trials":313,"activeCount":101},[],{"trials":315,"activeCount":101},[],{"intervention":317,"totalTrials":97,"cells":318},"MDMA HCl",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":336,"PHASE4":338,"NA":340},{"trials":320,"activeCount":101},[],{"trials":322,"activeCount":101},[],{"trials":324,"activeCount":97,"soonestReadout":329},[325],{"nctId":326,"briefTitle":327,"status":113,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT07469098","Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events",[90],"2028-12-31","2029-03-31","2025-12-24",168,[334],"PTSD",[317],{"trials":337,"activeCount":101},[],{"trials":339,"activeCount":101},[],{"trials":341,"activeCount":101},[],{"intervention":41,"totalTrials":97,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":345,"activeCount":101},[],{"trials":347,"activeCount":101},[],{"trials":349,"activeCount":97,"soonestReadout":40},[350],{"nctId":38,"briefTitle":39,"status":113,"phases":351,"primaryCompletion":40,"completion":352,"start":353,"enrollment":248,"conditions":354,"interventions":363},[90],"2029-11","2021-04-12",[355,356,357,358,359,360,361,362],"Ovarian Neoplasms","Carcinoma, Ovarian Epithelial","Neoplasm of Stomach","Ovarian Diseases","Genital Neoplasms, Female","Ovarian Epithelial Tumor","Urogenital Neoplasms","Neoplasms, Glandular and Epithelial",[41,364],"Lenvatinib",{"trials":366,"activeCount":101},[],{"trials":368,"activeCount":101},[],{"trials":370,"activeCount":101},[],{"intervention":364,"totalTrials":97,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":374,"activeCount":101},[],{"trials":376,"activeCount":101},[],{"trials":378,"activeCount":97,"soonestReadout":40},[379],{"nctId":38,"briefTitle":39,"status":113,"phases":380,"primaryCompletion":40,"completion":352,"start":353,"enrollment":248,"conditions":381,"interventions":382},[90],[355,356,357,358,359,360,361,362],[41,364],{"trials":384,"activeCount":101},[],{"trials":386,"activeCount":101},[],{"trials":388,"activeCount":101},[],{"intervention":86,"totalTrials":97,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":392,"activeCount":101},[],{"trials":394,"activeCount":101},[],{"trials":396,"activeCount":97,"soonestReadout":85},[397],{"nctId":83,"briefTitle":84,"status":113,"phases":398,"primaryCompletion":85,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":406},[90],"2030-07-30","2023-07-11",33,[403,404,405],"Advanced Glioblastoma","Metastatic Melanoma in the Central Nervous System","MGMT-Unmethylated Glioblastoma",[86,407],"Nivolumab 10 MG\u002F1 ML Intravenous Solution [OPDIVO]",{"trials":409,"activeCount":101},[],{"trials":411,"activeCount":101},[],{"trials":413,"activeCount":101},[],{"intervention":407,"totalTrials":97,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":417,"activeCount":101},[],{"trials":419,"activeCount":101},[],{"trials":421,"activeCount":97,"soonestReadout":85},[422],{"nctId":83,"briefTitle":84,"status":113,"phases":423,"primaryCompletion":85,"completion":399,"start":400,"enrollment":401,"conditions":424,"interventions":425},[90],[403,404,405],[86,407],{"trials":427,"activeCount":101},[],{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":101},[],{"intervention":51,"totalTrials":97,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":448,"PHASE4":450,"NA":452},{"trials":435,"activeCount":101},[],{"trials":437,"activeCount":101},[],{"trials":439,"activeCount":97,"soonestReadout":50},[440],{"nctId":48,"briefTitle":49,"status":261,"phases":441,"primaryCompletion":50,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":447},[90],"2026-07","2024-04-01",30,[446],"Williams Syndrome",[51],{"trials":449,"activeCount":101},[],{"trials":451,"activeCount":101},[],{"trials":453,"activeCount":101},[],{"intervention":455,"totalTrials":97,"cells":456},"SHB-02-CD19",{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":475,"PHASE4":477,"NA":479},{"trials":458,"activeCount":101},[],{"trials":460,"activeCount":101},[],{"trials":462,"activeCount":97,"soonestReadout":467},[463],{"nctId":464,"briefTitle":465,"status":185,"phases":466,"primaryCompletion":467,"completion":468,"start":55,"enrollment":469,"conditions":470,"interventions":474},"NCT07503353","A Phase 1\u002F2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies",[89,90],"2029-06","2030-01",50,[471,472,473],"B Cell Malignancies","Acute Lymphobkastic Leukemia","Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)",[455],{"trials":476,"activeCount":101},[],{"trials":478,"activeCount":101},[],{"trials":480,"activeCount":101},[],{"intervention":482,"totalTrials":483,"cells":484},"Metformin",2,{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":486,"activeCount":101},[],{"trials":488,"activeCount":101},[489],{"nctId":490,"briefTitle":491,"status":208,"phases":492,"primaryCompletion":493,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT02149459","Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy",[89],"2018-07","2014-06",18,[497],"Brain Neoplasms",[482],{"trials":500,"activeCount":101},[],{"trials":502,"activeCount":101},[],{"trials":504,"activeCount":101},[],{"trials":506,"activeCount":97,"soonestReadout":70},[507],{"nctId":68,"briefTitle":69,"status":185,"phases":508,"primaryCompletion":70,"completion":70,"start":509,"enrollment":8,"conditions":510,"interventions":513},[],"2025-09-01",[511,512],"Polycystic Ovary Syndrome","Microbial Colonization",[71,482],{"intervention":56,"totalTrials":97,"cells":515},{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":517,"activeCount":101},[],{"trials":519,"activeCount":101},[],{"trials":521,"activeCount":101},[],{"trials":523,"activeCount":101},[],{"trials":525,"activeCount":101},[],{"trials":527,"activeCount":97,"soonestReadout":55},[528],{"nctId":53,"briefTitle":54,"status":113,"phases":529,"primaryCompletion":55,"completion":65,"start":530,"enrollment":531,"conditions":532,"interventions":534},[93],"2024-01-22",60,[533],"Dientamoeba Fragilis Infection",[56],{"intervention":71,"totalTrials":97,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":538,"activeCount":101},[],{"trials":540,"activeCount":101},[],{"trials":542,"activeCount":101},[],{"trials":544,"activeCount":101},[],{"trials":546,"activeCount":101},[],{"trials":548,"activeCount":97,"soonestReadout":70},[549],{"nctId":68,"briefTitle":69,"status":185,"phases":550,"primaryCompletion":70,"completion":70,"start":509,"enrollment":8,"conditions":551,"interventions":552},[],[511,512],[71,482],{"intervention":61,"totalTrials":97,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":556,"activeCount":101},[],{"trials":558,"activeCount":101},[],{"trials":560,"activeCount":101},[],{"trials":562,"activeCount":101},[],{"trials":564,"activeCount":101},[],{"trials":566,"activeCount":97,"soonestReadout":60},[567],{"nctId":58,"briefTitle":59,"status":185,"phases":568,"primaryCompletion":60,"completion":75,"start":569,"enrollment":444,"conditions":570,"interventions":571},[],"2026-02",[29],[61],{"intervention":573,"totalTrials":574,"cells":575},"Melatonin",3,{"EARLY_PHASE1":576,"PHASE1":589,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":614},{"trials":577,"activeCount":101},[578],{"nctId":579,"briefTitle":580,"status":208,"phases":581,"primaryCompletion":582,"completion":583,"start":584,"enrollment":444,"conditions":585,"interventions":588},"NCT02644590","The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1",[88],"2016-09","2017-02","2016-02",[586,587],"Diabetes Mellitus, Type 1","Hypertension",[573],{"trials":590,"activeCount":101},[591],{"nctId":592,"briefTitle":593,"status":208,"phases":594,"conditions":595,"interventions":597},"NCT00282061","Synchronization and Desynchronization Between Circadian Rhythms in Patients With Delayed Sleep Phase Syndrome (DSPS)",[89],[596],"Delayed Sleep Phase Syndrome",[573],{"trials":599,"activeCount":101},[],{"trials":601,"activeCount":101},[],{"trials":603,"activeCount":101},[604],{"nctId":605,"briefTitle":606,"status":607,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":531,"conditions":611,"interventions":613},"NCT02424071","The Effect of Premedication With Melatonin on Postoperative Recovery From Bariatric Surgery","COMPLETED",[92],"2016-04","2015-07",[612],"Recovery From Bariatric Surgery",[573],{"trials":615,"activeCount":101},[],{"intervention":617,"totalTrials":574,"cells":618},"normal saline",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":632,"PHASE3":634,"PHASE4":649,"NA":663},{"trials":620,"activeCount":101},[],{"trials":622,"activeCount":101},[623],{"nctId":624,"briefTitle":625,"status":208,"phases":626,"primaryCompletion":246,"completion":246,"start":627,"enrollment":444,"conditions":628,"interventions":630},"NCT01219322","Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Anesthetized Children",[89],"2010-10",[629],"General Anesthesia",[631,617],"Sodium bicarbonate",{"trials":633,"activeCount":101},[],{"trials":635,"activeCount":101},[636],{"nctId":637,"briefTitle":638,"status":208,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":646},"NCT01458873","Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Spontaneously Breathing Adult Volunteers",[90,91],"2012-12","2011-10",20,[644,645],"Infiltration","Extravasation",[647,648,617],"sodium bicarbonate 4.2%","diluted sodium bicarbonate 2.1%",{"trials":650,"activeCount":101},[651],{"nctId":652,"briefTitle":653,"status":208,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":531,"conditions":658,"interventions":660},"NCT01930734","Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients",[92],"2015-10","2016-10","2013-10",[659],"Heart Failure",[661,662],"Dobutamine","Normal Saline",{"trials":664,"activeCount":101},[],{"intervention":666,"totalTrials":483,"cells":667},"Lidocaine",{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":672,"PHASE3":674,"PHASE4":676,"NA":700},{"trials":669,"activeCount":101},[],{"trials":671,"activeCount":101},[],{"trials":673,"activeCount":101},[],{"trials":675,"activeCount":101},[],{"trials":677,"activeCount":101},[678,690],{"nctId":679,"briefTitle":680,"status":607,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":689},"NCT02097017","Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation",[92],"2018-08-01","2016-07-01",134,[686,687,688],"Pain Alleviation","Dilatation and Evacuation","Laminaria Placement",[666],{"nctId":691,"briefTitle":692,"status":208,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":531,"conditions":697,"interventions":699},"NCT02762656","The Effect of Perioperative Lidocaine Intravenous Infusion on Postoperative Recovery After Spine Surgery.",[92],"2017-06","2017-08","2016-06",[698],"Spinal Diseases",[666],{"trials":701,"activeCount":101},[],{"intervention":703,"totalTrials":483,"cells":704},"Allopurinol",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":723,"NA":736},{"trials":706,"activeCount":101},[],{"trials":708,"activeCount":101},[],{"trials":710,"activeCount":101},[],{"trials":712,"activeCount":101},[713],{"nctId":714,"briefTitle":715,"status":607,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT01092221","Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and\u002For Antipsychotics in Patients in a Bipolar Manic Episode",[91],"2011-04","2010-05",180,[721],"Mania",[703],{"trials":724,"activeCount":101},[725],{"nctId":726,"briefTitle":727,"status":607,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT00864825","Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia",[92],"2009-12","2010-01","2009-08",248,[15,734],"Schizoaffective Disorder",[703],{"trials":737,"activeCount":101},[],{"intervention":739,"totalTrials":483,"cells":740},"Risperidone",{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":749,"NA":773},{"trials":742,"activeCount":101},[],{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":101},[],{"trials":748,"activeCount":101},[],{"trials":750,"activeCount":101},[751,759],{"nctId":752,"briefTitle":753,"status":208,"phases":754,"primaryCompletion":641,"start":755,"enrollment":531,"conditions":756,"interventions":757},"NCT00480844","Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone",[92],"2008-10",[15],[758,739],"Sertindole",{"nctId":760,"briefTitle":761,"status":762,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":771},"NCT02063945","Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders","TERMINATED",[92],"2018-02-01","2017-02-01",5,[768,769,770],"Attention Deficit\u002FHyperactivity Disorder","Oppositional Defiant Disorder","Conduct Disorder",[772,739],"Methylphenidate",{"trials":774,"activeCount":101},[],{"intervention":232,"totalTrials":483,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":789,"NA":803},{"trials":778,"activeCount":101},[],{"trials":780,"activeCount":101},[],{"trials":782,"activeCount":101},[],{"trials":784,"activeCount":101},[785],{"nctId":223,"briefTitle":224,"status":208,"phases":786,"primaryCompletion":226,"start":227,"enrollment":228,"conditions":787,"interventions":788},[90,91],[230],[169,232],{"trials":790,"activeCount":101},[791],{"nctId":792,"briefTitle":793,"status":794,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":101,"conditions":798,"interventions":800},"NCT03529097","Evaluation of the Roll of IV Fluids in the Treatment of Renal Colic","WITHDRAWN",[92],"2019-12-31","2018-06-01",[799],"Renal Colic",[801,232,802],"0.9% Sodium-chloride","Optalgin, Voltaren, Morphine",{"trials":804,"activeCount":101},[],{"intervention":806,"totalTrials":97,"cells":807},"Dapagliflozin 10 MG [Farxiga]",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":816,"NA":828},{"trials":809,"activeCount":101},[],{"trials":811,"activeCount":101},[],{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":101},[],{"trials":817,"activeCount":101},[818],{"nctId":819,"briefTitle":820,"status":208,"phases":821,"primaryCompletion":822,"completion":823,"start":764,"enrollment":824,"conditions":825,"interventions":827},"NCT03398577","Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease",[92],"2018-08-31","2018-12-31",61,[826],"Coronary Disease With Diabetes Mellitus",[806],{"trials":829,"activeCount":101},[],{"intervention":831,"totalTrials":97,"cells":832},"Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":854},{"trials":834,"activeCount":101},[],{"trials":836,"activeCount":101},[],{"trials":838,"activeCount":101},[],{"trials":840,"activeCount":101},[],{"trials":842,"activeCount":101},[843],{"nctId":844,"briefTitle":845,"status":208,"phases":846,"primaryCompletion":847,"completion":848,"start":849,"enrollment":850,"conditions":851,"interventions":853},"NCT00290056","Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial",[92],"2009-11","2010-06","2005-11",105,[18,852],"Arrhythmia",[831],{"trials":855,"activeCount":101},[],{"intervention":857,"totalTrials":97,"cells":858},"Zinc",{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":878},{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":101},[],{"trials":866,"activeCount":101},[],{"trials":868,"activeCount":101},[869],{"nctId":870,"briefTitle":871,"status":607,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":8,"conditions":875,"interventions":877},"NCT00449592","Oral Zinc Therapy for the Prevention of Mucositis",[92],"2008-09","2007-04",[876],"Mucositis",[857],{"trials":879,"activeCount":101},[],{"intervention":881,"totalTrials":97,"cells":882},"doxorubicin, cytoxan",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":900},{"trials":884,"activeCount":101},[],{"trials":886,"activeCount":101},[],{"trials":888,"activeCount":101},[],{"trials":890,"activeCount":101},[],{"trials":892,"activeCount":101},[893],{"nctId":894,"briefTitle":895,"status":208,"phases":896,"conditions":897,"interventions":899},"NCT00339118","EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children",[92],[898],"Rhabdomyosarcoma",[881],{"trials":901,"activeCount":101},[],{"intervention":903,"totalTrials":97,"cells":904},"Choriogonadotropin alfa",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":926},{"trials":906,"activeCount":101},[],{"trials":908,"activeCount":101},[],{"trials":910,"activeCount":101},[],{"trials":912,"activeCount":101},[],{"trials":914,"activeCount":101},[915],{"nctId":916,"briefTitle":917,"status":208,"phases":918,"primaryCompletion":694,"completion":694,"start":919,"enrollment":920,"conditions":921,"interventions":924},"NCT02825290","Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study",[92],"2016-07",62,[922,923],"Embryo Transfer","Luteal Support",[903,925],"Triptorelin acetate",{"trials":927,"activeCount":101},[],{"intervention":925,"totalTrials":97,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":944},{"trials":931,"activeCount":101},[],{"trials":933,"activeCount":101},[],{"trials":935,"activeCount":101},[],{"trials":937,"activeCount":101},[],{"trials":939,"activeCount":101},[940],{"nctId":916,"briefTitle":917,"status":208,"phases":941,"primaryCompletion":694,"completion":694,"start":919,"enrollment":920,"conditions":942,"interventions":943},[92],[922,923],[903,925],{"trials":945,"activeCount":101},[],{"intervention":947,"totalTrials":97,"cells":948},"The cessation of anti-aggregative treatment for 10 days",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":967},{"trials":950,"activeCount":101},[],{"trials":952,"activeCount":101},[],{"trials":954,"activeCount":101},[],{"trials":956,"activeCount":101},[],{"trials":958,"activeCount":101},[959],{"nctId":960,"briefTitle":961,"status":208,"phases":962,"start":963,"conditions":964,"interventions":966},"NCT00426400","Anti-Aggregative Therapy and Laser Iridectomy",[92],"2006-03",[965],"Eyes With Narrow Angle",[947],{"trials":968,"activeCount":101},[],{"intervention":970,"totalTrials":97,"cells":971},"Testoviron",{"EARLY_PHASE1":972,"PHASE1":974,"PHASE2":976,"PHASE3":978,"PHASE4":980,"NA":990},{"trials":973,"activeCount":101},[],{"trials":975,"activeCount":101},[],{"trials":977,"activeCount":101},[],{"trials":979,"activeCount":101},[],{"trials":981,"activeCount":101},[982],{"nctId":983,"briefTitle":984,"status":208,"phases":985,"start":986,"conditions":987,"interventions":989},"NCT00260390","Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial",[92],"2004-09",[988],"Dysthymic Disorder",[970],{"trials":991,"activeCount":101},[],{"intervention":993,"totalTrials":97,"cells":994},"Acetyl-Choline Esterase Inhibitors and Choline supplements",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1016},{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":101},[],{"trials":1000,"activeCount":101},[],{"trials":1002,"activeCount":101},[],{"trials":1004,"activeCount":101},[1005],{"nctId":1006,"briefTitle":1007,"status":208,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT01098383","Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders",[92],"2017-12","2010-03",84,[1013],"Autism",[993,1015],"Indistinguishable placebo tablets, matching both donepezil and choline",{"trials":1017,"activeCount":101},[],{"intervention":1015,"totalTrials":97,"cells":1019},{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1034},{"trials":1021,"activeCount":101},[],{"trials":1023,"activeCount":101},[],{"trials":1025,"activeCount":101},[],{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":101},[1030],{"nctId":1006,"briefTitle":1007,"status":208,"phases":1031,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1032,"interventions":1033},[92],[1013],[993,1015],{"trials":1035,"activeCount":101},[],{"intervention":1037,"totalTrials":97,"cells":1038},"Lanreotide autogel",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1045,"PHASE4":1047,"NA":1057},{"trials":1040,"activeCount":101},[],{"trials":1042,"activeCount":101},[],{"trials":1044,"activeCount":101},[],{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":101},[1049],{"nctId":1050,"briefTitle":1051,"status":607,"phases":1052,"primaryCompletion":1053,"completion":1053,"start":247,"enrollment":574,"conditions":1054,"interventions":1056},"NCT01070758","Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy",[92],"2015-02",[1055],"Congenital Hyperinsulinism",[1037],{"trials":1058,"activeCount":101},[],{"intervention":1060,"totalTrials":97,"cells":1061},"recombinant gonadotropins",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1084},{"trials":1063,"activeCount":101},[],{"trials":1065,"activeCount":101},[],{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":101},[],{"trials":1071,"activeCount":101},[1072],{"nctId":1073,"briefTitle":1074,"status":208,"phases":1075,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":1080,"interventions":1082},"NCT02992808","Androgenic Profile Following Controlled Ovarian Stimulation",[92],"2018-01","2020-01","2016-12",100,[1081],"Infertility, Female",[1060,1083],"HP-HMG",{"trials":1085,"activeCount":101},[],{"intervention":1083,"totalTrials":97,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1102},{"trials":1089,"activeCount":101},[],{"trials":1091,"activeCount":101},[],{"trials":1093,"activeCount":101},[],{"trials":1095,"activeCount":101},[],{"trials":1097,"activeCount":101},[1098],{"nctId":1073,"briefTitle":1074,"status":208,"phases":1099,"primaryCompletion":1076,"completion":1077,"start":1078,"enrollment":1079,"conditions":1100,"interventions":1101},[92],[1081],[1060,1083],{"trials":1103,"activeCount":101},[],{"intervention":1105,"totalTrials":97,"cells":1106},"Tenofovir disoproxil\u002Femtricitabine\u002Frilpivirine",{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1115,"NA":1128},{"trials":1108,"activeCount":101},[],{"trials":1110,"activeCount":101},[],{"trials":1112,"activeCount":101},[],{"trials":1114,"activeCount":101},[],{"trials":1116,"activeCount":101},[1117],{"nctId":1118,"briefTitle":1119,"status":762,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1126},"NCT02447016","Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera",[92],"2016-12-21","2015-05",25,[1125],"HIV",[1105,1127],"Tenofovir disoproxil\u002Femtricitabine\u002Fefavirenz",{"trials":1129,"activeCount":101},[],{"intervention":1127,"totalTrials":97,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1146},{"trials":1133,"activeCount":101},[],{"trials":1135,"activeCount":101},[],{"trials":1137,"activeCount":101},[],{"trials":1139,"activeCount":101},[],{"trials":1141,"activeCount":101},[1142],{"nctId":1118,"briefTitle":1119,"status":762,"phases":1143,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":1123,"conditions":1144,"interventions":1145},[92],[1125],[1105,1127],{"trials":1147,"activeCount":101},[],{"intervention":1149,"totalTrials":97,"cells":1150},"ceftriaxone",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1174},{"trials":1152,"activeCount":101},[],{"trials":1154,"activeCount":101},[],{"trials":1156,"activeCount":101},[],{"trials":1158,"activeCount":101},[],{"trials":1160,"activeCount":101},[1161],{"nctId":1162,"briefTitle":1163,"status":208,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":164,"conditions":1168,"interventions":1170},"NCT02224040","Typhoid Fever: Combined vs. Single Antibiotic Therapy",[92],"2014-12","2015-08","2013-08",[1169],"Typhoid Fever",[1149,1171,1172,1173],"ceftriaxone and azithromycin","azithromycin","azithromycin and cefixime",{"trials":1175,"activeCount":101},[],{"intervention":1171,"totalTrials":97,"cells":1177},{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1182,"PHASE3":1184,"PHASE4":1186,"NA":1192},{"trials":1179,"activeCount":101},[],{"trials":1181,"activeCount":101},[],{"trials":1183,"activeCount":101},[],{"trials":1185,"activeCount":101},[],{"trials":1187,"activeCount":101},[1188],{"nctId":1162,"briefTitle":1163,"status":208,"phases":1189,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":164,"conditions":1190,"interventions":1191},[92],[1169],[1149,1171,1172,1173],{"trials":1193,"activeCount":101},[],{"intervention":1172,"totalTrials":97,"cells":1195},{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1202,"PHASE4":1204,"NA":1210},{"trials":1197,"activeCount":101},[],{"trials":1199,"activeCount":101},[],{"trials":1201,"activeCount":101},[],{"trials":1203,"activeCount":101},[],{"trials":1205,"activeCount":101},[1206],{"nctId":1162,"briefTitle":1163,"status":208,"phases":1207,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":164,"conditions":1208,"interventions":1209},[92],[1169],[1149,1171,1172,1173],{"trials":1211,"activeCount":101},[],{"intervention":1173,"totalTrials":97,"cells":1213},{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1228},{"trials":1215,"activeCount":101},[],{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":101},[],{"trials":1221,"activeCount":101},[],{"trials":1223,"activeCount":101},[1224],{"nctId":1162,"briefTitle":1163,"status":208,"phases":1225,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":164,"conditions":1226,"interventions":1227},[92],[1169],[1149,1171,1172,1173],{"trials":1229,"activeCount":101},[],{"intervention":1231,"totalTrials":97,"cells":1232},"Aspirin",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1253},{"trials":1234,"activeCount":101},[],{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":101},[],{"trials":1242,"activeCount":101},[1243],{"nctId":1244,"briefTitle":1245,"status":607,"phases":1246,"primaryCompletion":227,"completion":227,"start":1247,"enrollment":264,"conditions":1248,"interventions":1252},"NCT02049762","Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy",[92],"2015-06",[1249,1250,1251],"Acute Coronary Syndrome","Platelet Function and Reactivity Tests","Novel P2Y12 Inhibitors",[1231],{"trials":1254,"activeCount":101},[],{"intervention":1256,"totalTrials":97,"cells":1257},"Prolonged antibiotic treatment",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1278},{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":101},[],{"trials":1263,"activeCount":101},[],{"trials":1265,"activeCount":101},[],{"trials":1267,"activeCount":101},[1268],{"nctId":1269,"briefTitle":1270,"status":208,"phases":1271,"primaryCompletion":1078,"completion":1009,"start":1272,"enrollment":1273,"conditions":1274,"interventions":1276},"NCT02012517","Antibiotic Prophylaxis in Prosthetic Breast Reconstructions",[92],"2014-01",160,[1275],"Surgical Site Infections",[1256,1277],"Short antibiotic course",{"trials":1279,"activeCount":101},[],{"intervention":1277,"totalTrials":97,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1296},{"trials":1283,"activeCount":101},[],{"trials":1285,"activeCount":101},[],{"trials":1287,"activeCount":101},[],{"trials":1289,"activeCount":101},[],{"trials":1291,"activeCount":101},[1292],{"nctId":1269,"briefTitle":1270,"status":208,"phases":1293,"primaryCompletion":1078,"completion":1009,"start":1272,"enrollment":1273,"conditions":1294,"interventions":1295},[92],[1275],[1256,1277],{"trials":1297,"activeCount":101},[],{"intervention":1299,"totalTrials":97,"cells":1300},"Isoflurane",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1323},{"trials":1302,"activeCount":101},[],{"trials":1304,"activeCount":101},[],{"trials":1306,"activeCount":101},[],{"trials":1308,"activeCount":101},[],{"trials":1310,"activeCount":101},[1311],{"nctId":1312,"briefTitle":1313,"status":762,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1321},"NCT01397331","Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery",[92],"2012-06-27","2010-07-01",28,[1319,1320],"Heart; Dysfunction Postoperative, Cardiac Surgery","Disorder; Heart, Functional, Postoperative, Cardiac Surgery",[1299,1322],"Propofol",{"trials":1324,"activeCount":101},[],{"intervention":1322,"totalTrials":97,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1341},{"trials":1328,"activeCount":101},[],{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":101},[],{"trials":1336,"activeCount":101},[1337],{"nctId":1312,"briefTitle":1313,"status":762,"phases":1338,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":1317,"conditions":1339,"interventions":1340},[92],[1319,1320],[1299,1322],{"trials":1342,"activeCount":101},[],{"intervention":1344,"totalTrials":97,"cells":1345},"Romosozumab",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1367},{"trials":1347,"activeCount":101},[],{"trials":1349,"activeCount":101},[],{"trials":1351,"activeCount":101},[],{"trials":1353,"activeCount":101},[],{"trials":1355,"activeCount":101},[1356],{"nctId":1357,"briefTitle":1358,"status":208,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":444,"conditions":1362,"interventions":1365},"NCT04597931","Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density",[92],"2023-11-15","2020-11-01",[1363,1364],"Osteoporosis Fracture","Spinal Cord Injuries",[1344,1366],"Zoledronic Acid",{"trials":1368,"activeCount":101},[],{"intervention":1366,"totalTrials":97,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1385},{"trials":1372,"activeCount":101},[],{"trials":1374,"activeCount":101},[],{"trials":1376,"activeCount":101},[],{"trials":1378,"activeCount":101},[],{"trials":1380,"activeCount":101},[1381],{"nctId":1357,"briefTitle":1358,"status":208,"phases":1382,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":444,"conditions":1383,"interventions":1384},[92],[1363,1364],[1344,1366],{"trials":1386,"activeCount":101},[],{"intervention":1388,"totalTrials":97,"cells":1389},"BNT162b2 vaccine",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1410},{"trials":1391,"activeCount":101},[],{"trials":1393,"activeCount":101},[],{"trials":1395,"activeCount":101},[],{"trials":1397,"activeCount":101},[],{"trials":1399,"activeCount":101},[1400],{"nctId":1401,"briefTitle":1402,"status":208,"phases":1403,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1409},"NCT05231005","Fourth BNT162b2 COVID-19 Vaccine Dose",[92],"2024-06-26","2021-12-27",1000,[1408],"COVID-19 Pandemic",[1388],{"trials":1411,"activeCount":101},[],{"intervention":1413,"totalTrials":97,"cells":1414},"Botox",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1434},{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":101},[],{"trials":1424,"activeCount":101},[1425],{"nctId":1426,"briefTitle":1427,"status":208,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":642,"conditions":1431,"interventions":1433},"NCT01500668","Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis",[92],"2013-12","2012-01",[1432],"Catocholamine Induced Finger Necrosis",[1413],{"trials":1435,"activeCount":101},[],{"intervention":1437,"totalTrials":97,"cells":1438},"Chewing Ticagrelor LD",{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1445,"PHASE4":1447,"NA":1457},{"trials":1440,"activeCount":101},[],{"trials":1442,"activeCount":101},[],{"trials":1444,"activeCount":101},[],{"trials":1446,"activeCount":101},[],{"trials":1448,"activeCount":101},[1449],{"nctId":1450,"briefTitle":1451,"status":208,"phases":1452,"primaryCompletion":1009,"start":583,"enrollment":1079,"conditions":1453,"interventions":1455},"NCT03016611","Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study",[92],[1249,1454],"STEMI",[1437,1456],"Chewing Prasugrel LD",{"trials":1458,"activeCount":101},[],{"intervention":1456,"totalTrials":97,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1475},{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[],{"trials":1468,"activeCount":101},[],{"trials":1470,"activeCount":101},[1471],{"nctId":1450,"briefTitle":1451,"status":208,"phases":1472,"primaryCompletion":1009,"start":583,"enrollment":1079,"conditions":1473,"interventions":1474},[92],[1249,1454],[1437,1456],{"trials":1476,"activeCount":101},[],{"intervention":1478,"totalTrials":97,"cells":1479},"Ulipristal acetate",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1497},{"trials":1481,"activeCount":101},[],{"trials":1483,"activeCount":101},[],{"trials":1485,"activeCount":101},[],{"trials":1487,"activeCount":101},[],{"trials":1489,"activeCount":101},[1490],{"nctId":1491,"briefTitle":1492,"status":208,"phases":1493,"primaryCompletion":1076,"completion":1076,"start":582,"enrollment":642,"conditions":1494,"interventions":1496},"NCT02601196","IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure",[92],[1495],"Women With Leiomyoma After at Least One Unsuccessful IVF Treatment",[1478],{"trials":1498,"activeCount":101},[],{"intervention":1500,"totalTrials":97,"cells":1501},"Pregabalin",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1521},{"trials":1503,"activeCount":101},[],{"trials":1505,"activeCount":101},[],{"trials":1507,"activeCount":101},[],{"trials":1509,"activeCount":101},[],{"trials":1511,"activeCount":101},[1512],{"nctId":1513,"briefTitle":1514,"status":208,"phases":1515,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":469,"conditions":1518,"interventions":1520},"NCT03748290","Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among SCI",[92],"2019-11","2018-08-23",[1364,1519],"Central Pain Syndrome",[1500],{"trials":1522,"activeCount":101},[],{"intervention":1524,"totalTrials":97,"cells":1525},"Sustained-release oral dalfampridine",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1534,"NA":1543},{"trials":1527,"activeCount":101},[],{"trials":1529,"activeCount":101},[],{"trials":1531,"activeCount":101},[],{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":101},[1536],{"nctId":1537,"briefTitle":1538,"status":208,"phases":1539,"primaryCompletion":1540,"completion":1540,"start":1540,"enrollment":444,"conditions":1541,"interventions":1542},"NCT02259361","Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS",[92],"2014-11",[24],[1524],{"trials":1544,"activeCount":101},[],{"intervention":1546,"totalTrials":97,"cells":1547},"Omeprazole",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1565},{"trials":1549,"activeCount":101},[],{"trials":1551,"activeCount":101},[],{"trials":1553,"activeCount":101},[],{"trials":1555,"activeCount":101},[],{"trials":1557,"activeCount":101},[1558],{"nctId":1559,"briefTitle":1560,"status":794,"phases":1561,"primaryCompletion":640,"completion":640,"start":640,"enrollment":101,"conditions":1562,"interventions":1563},"NCT01016717","Clopidogrel Proton-Pump Inhibitors Study",[92],[18],[1546,1564],"Pantoprazole",{"trials":1566,"activeCount":101},[],{"intervention":1564,"totalTrials":97,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1575,"PHASE4":1577,"NA":1583},{"trials":1570,"activeCount":101},[],{"trials":1572,"activeCount":101},[],{"trials":1574,"activeCount":101},[],{"trials":1576,"activeCount":101},[],{"trials":1578,"activeCount":101},[1579],{"nctId":1559,"briefTitle":1560,"status":794,"phases":1580,"primaryCompletion":640,"completion":640,"start":640,"enrollment":101,"conditions":1581,"interventions":1582},[92],[18],[1546,1564],{"trials":1584,"activeCount":101},[],{"intervention":1586,"totalTrials":97,"cells":1587},"Chewing Ticagrelor",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1594,"PHASE4":1596,"NA":1608},{"trials":1589,"activeCount":101},[],{"trials":1591,"activeCount":101},[],{"trials":1593,"activeCount":101},[],{"trials":1595,"activeCount":101},[],{"trials":1597,"activeCount":101},[1598],{"nctId":1599,"briefTitle":1600,"status":607,"phases":1601,"primaryCompletion":227,"completion":227,"start":1602,"enrollment":469,"conditions":1603,"interventions":1606},"NCT02725099","Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients",[92],"2016-05",[1604,1605],"Acute Coronary Syndromes","ST Elevation Myocardial Infarction",[1586,1607],"Oral Ticagrelor",{"trials":1609,"activeCount":101},[],{"intervention":1607,"totalTrials":97,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1618,"PHASE4":1620,"NA":1626},{"trials":1613,"activeCount":101},[],{"trials":1615,"activeCount":101},[],{"trials":1617,"activeCount":101},[],{"trials":1619,"activeCount":101},[],{"trials":1621,"activeCount":101},[1622],{"nctId":1599,"briefTitle":1600,"status":607,"phases":1623,"primaryCompletion":227,"completion":227,"start":1602,"enrollment":469,"conditions":1624,"interventions":1625},[92],[1604,1605],[1586,1607],{"trials":1627,"activeCount":101},[],{"intervention":1629,"totalTrials":97,"cells":1630},"ropinirole",{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1637,"PHASE4":1639,"NA":1649},{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[],{"trials":1636,"activeCount":101},[],{"trials":1638,"activeCount":101},[],{"trials":1640,"activeCount":101},[1641],{"nctId":1642,"briefTitle":1643,"status":208,"phases":1644,"start":1645,"enrollment":531,"conditions":1646,"interventions":1648},"NCT00335205","A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.",[92],"2003-04",[1647,29],"Bipolar Disorder",[1629],{"trials":1650,"activeCount":101},[],{"intervention":1652,"totalTrials":97,"cells":1653},"Tredaptive",{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1660,"PHASE4":1662,"NA":1673},{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":101},[],{"trials":1659,"activeCount":101},[],{"trials":1661,"activeCount":101},[],{"trials":1663,"activeCount":101},[1664],{"nctId":1665,"briefTitle":1666,"status":762,"phases":1667,"primaryCompletion":1668,"completion":1668,"start":1669,"enrollment":27,"conditions":1670,"interventions":1672},"NCT01052311","The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients",[92],"2013-01","2010-07",[18,1671],"Dyslipidemia",[1652,1652],{"trials":1674,"activeCount":101},[],{"intervention":1676,"totalTrials":97,"cells":1677},"Celestone",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1700},{"trials":1679,"activeCount":101},[],{"trials":1681,"activeCount":101},[],{"trials":1683,"activeCount":101},[],{"trials":1685,"activeCount":101},[],{"trials":1687,"activeCount":101},[1688],{"nctId":1689,"briefTitle":1690,"status":208,"phases":1691,"primaryCompletion":1692,"completion":1693,"start":656,"enrollment":164,"conditions":1694,"interventions":1698},"NCT02930057","Transforaminal Epidural Steroid Injection With Pulsed Radiofrequency for Chronic Lumbosacral Radicular Pain Management",[92],"2017-10","2018-10",[1695,1696,1697],"Radicular; Neuropathic, Lumbar, Lumbosacral","Low Back Pain","Back Pain With Radiation",[1676,1699],"Control",{"trials":1701,"activeCount":101},[],{"intervention":1699,"totalTrials":97,"cells":1703},{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1710,"PHASE4":1712,"NA":1718},{"trials":1705,"activeCount":101},[],{"trials":1707,"activeCount":101},[],{"trials":1709,"activeCount":101},[],{"trials":1711,"activeCount":101},[],{"trials":1713,"activeCount":101},[1714],{"nctId":1689,"briefTitle":1690,"status":208,"phases":1715,"primaryCompletion":1692,"completion":1693,"start":656,"enrollment":164,"conditions":1716,"interventions":1717},[92],[1695,1696,1697],[1676,1699],{"trials":1719,"activeCount":101},[],{"intervention":758,"totalTrials":97,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1736},{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[],{"trials":1727,"activeCount":101},[],{"trials":1729,"activeCount":101},[],{"trials":1731,"activeCount":101},[1732],{"nctId":752,"briefTitle":753,"status":208,"phases":1733,"primaryCompletion":641,"start":755,"enrollment":531,"conditions":1734,"interventions":1735},[92],[15],[758,739],{"trials":1737,"activeCount":101},[],{"intervention":1739,"totalTrials":97,"cells":1740},"Metformin plus vildagliptin",{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1749,"NA":1761},{"trials":1742,"activeCount":101},[],{"trials":1744,"activeCount":101},[],{"trials":1746,"activeCount":101},[],{"trials":1748,"activeCount":101},[],{"trials":1750,"activeCount":101},[1751],{"nctId":1752,"briefTitle":1753,"status":607,"phases":1754,"primaryCompletion":609,"completion":609,"start":1755,"enrollment":531,"conditions":1756,"interventions":1759},"NCT01604213","Effects of Vildagliptin\u002FMetformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease",[92],"2012-09",[1757,1758],"Type 2 Diabetes Mellitus","Ischemic Heart Disease",[1739,1760],"Metformin only",{"trials":1762,"activeCount":101},[],{"intervention":1760,"totalTrials":97,"cells":1764},{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1779},{"trials":1766,"activeCount":101},[],{"trials":1768,"activeCount":101},[],{"trials":1770,"activeCount":101},[],{"trials":1772,"activeCount":101},[],{"trials":1774,"activeCount":101},[1775],{"nctId":1752,"briefTitle":1753,"status":607,"phases":1776,"primaryCompletion":609,"completion":609,"start":1755,"enrollment":531,"conditions":1777,"interventions":1778},[92],[1757,1758],[1739,1760],{"trials":1780,"activeCount":101},[],{"intervention":1782,"totalTrials":97,"cells":1783},"oral 5-ASA+\u002F-topical 5-ASA+IV corticosteroids \u002F PO Methylprednisolone",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1790,"PHASE4":1792,"NA":1805},{"trials":1785,"activeCount":101},[],{"trials":1787,"activeCount":101},[],{"trials":1789,"activeCount":101},[],{"trials":1791,"activeCount":101},[],{"trials":1793,"activeCount":101},[1794],{"nctId":1795,"briefTitle":1796,"status":607,"phases":1797,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT01941589","Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis",[92],"2021-04","2013-09",149,[1802],"Ulcerative Colitis",[1782,1804],"corticosteroids only",{"trials":1806,"activeCount":101},[],{"intervention":1804,"totalTrials":97,"cells":1808},{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1823},{"trials":1810,"activeCount":101},[],{"trials":1812,"activeCount":101},[],{"trials":1814,"activeCount":101},[],{"trials":1816,"activeCount":101},[],{"trials":1818,"activeCount":101},[1819],{"nctId":1795,"briefTitle":1796,"status":607,"phases":1820,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":1800,"conditions":1821,"interventions":1822},[92],[1802],[1782,1804],{"trials":1824,"activeCount":101},[],{"intervention":1826,"totalTrials":97,"cells":1827},"amantadine sulphate",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1850},{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[],{"trials":1833,"activeCount":101},[],{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[1838],{"nctId":1839,"briefTitle":1840,"status":607,"phases":1841,"primaryCompletion":847,"completion":847,"start":1842,"enrollment":444,"conditions":1843,"interventions":1849},"NCT00950196","Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia",[92],"2008-11",[1844,1845,1846,1847,1848],"Ataxia","Chorea","Dystonia","Parkinsonism","Fatigue",[1826],{"trials":1851,"activeCount":101},[],{"intervention":1853,"totalTrials":97,"cells":1854},"rFVIIa-FEIBA therapy for hemophilia A inhibitors",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1874},{"trials":1856,"activeCount":101},[],{"trials":1858,"activeCount":101},[],{"trials":1860,"activeCount":101},[],{"trials":1862,"activeCount":101},[],{"trials":1864,"activeCount":101},[1865],{"nctId":1866,"briefTitle":1867,"status":607,"phases":1868,"primaryCompletion":1842,"completion":847,"start":1869,"enrollment":766,"conditions":1870,"interventions":1872},"NCT00284193","Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII",[92],"2005-01",[1871],"Hemophilia A",[1853,1873],"FEIBA- Activated Prothrombin Complexes",{"trials":1875,"activeCount":101},[],{"intervention":1873,"totalTrials":97,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1892},{"trials":1879,"activeCount":101},[],{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[1888],{"nctId":1866,"briefTitle":1867,"status":607,"phases":1889,"primaryCompletion":1842,"completion":847,"start":1869,"enrollment":766,"conditions":1890,"interventions":1891},[92],[1871],[1853,1873],{"trials":1893,"activeCount":101},[],{"intervention":661,"totalTrials":97,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1902,"PHASE4":1904,"NA":1910},{"trials":1897,"activeCount":101},[],{"trials":1899,"activeCount":101},[],{"trials":1901,"activeCount":101},[],{"trials":1903,"activeCount":101},[],{"trials":1905,"activeCount":101},[1906],{"nctId":652,"briefTitle":653,"status":208,"phases":1907,"primaryCompletion":655,"completion":656,"start":657,"enrollment":531,"conditions":1908,"interventions":1909},[92],[659],[661,662],{"trials":1911,"activeCount":101},[],{"intervention":1913,"totalTrials":97,"cells":1914},"D-cycloserine",{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1933},{"trials":1916,"activeCount":101},[],{"trials":1918,"activeCount":101},[],{"trials":1920,"activeCount":101},[],{"trials":1922,"activeCount":101},[],{"trials":1924,"activeCount":101},[1925],{"nctId":1926,"briefTitle":1927,"status":208,"phases":1928,"primaryCompletion":1078,"completion":227,"start":696,"enrollment":531,"conditions":1929,"interventions":1931},"NCT02772211","D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression",[92],[1930],"Treatment Resistant Depression",[1932,1913],"Ketamine",{"trials":1934,"activeCount":101},[],{"intervention":801,"totalTrials":97,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1945,"NA":1951},{"trials":1938,"activeCount":101},[],{"trials":1940,"activeCount":101},[],{"trials":1942,"activeCount":101},[],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[1947],{"nctId":792,"briefTitle":793,"status":794,"phases":1948,"primaryCompletion":796,"completion":796,"start":797,"enrollment":101,"conditions":1949,"interventions":1950},[92],[799],[801,232,802],{"trials":1952,"activeCount":101},[],{"intervention":802,"totalTrials":97,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1963,"NA":1969},{"trials":1956,"activeCount":101},[],{"trials":1958,"activeCount":101},[],{"trials":1960,"activeCount":101},[],{"trials":1962,"activeCount":101},[],{"trials":1964,"activeCount":101},[1965],{"nctId":792,"briefTitle":793,"status":794,"phases":1966,"primaryCompletion":796,"completion":796,"start":797,"enrollment":101,"conditions":1967,"interventions":1968},[92],[799],[801,232,802],{"trials":1970,"activeCount":101},[],{"intervention":1972,"totalTrials":97,"cells":1973},"Sub Lingual Ticagrelor",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1982,"NA":1992},{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[],{"trials":1983,"activeCount":101},[1984],{"nctId":1985,"briefTitle":1986,"status":607,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":610,"enrollment":469,"conditions":1989,"interventions":1991},"NCT02402400","Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome\u002FNon ST-elevation Myocardial Infarction - A Platelet Reactivity Study",[92],"2016-03",[1604,1990],"Non ST Elevation Myocardial Infarction",[1972],{"trials":1993,"activeCount":101},[],{"intervention":1995,"totalTrials":483,"cells":1996},"minocycline",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2027,"NA":2029},{"trials":1998,"activeCount":101},[],{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[],{"trials":2004,"activeCount":101},[2005,2017],{"nctId":2006,"briefTitle":2007,"status":208,"phases":2008,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":2012,"conditions":2013,"interventions":2014},"NCT01320982","Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder",[91],"2012-06","2012-07","2011-03",400,[15,734],[1995,2015,2016],"pramipexole","acetylsalicylic acid",{"nctId":2018,"briefTitle":2019,"status":208,"phases":2020,"primaryCompletion":2011,"completion":2021,"start":1010,"enrollment":444,"conditions":2022,"interventions":2024},"NCT01083420","The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus",[91],"2012-03",[2023],"Oral Lichen Planus",[2025,2026],"Minocycline","Dexamethasone",{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"intervention":647,"totalTrials":483,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2052,"NA":2054},{"trials":2034,"activeCount":101},[],{"trials":2036,"activeCount":101},[],{"trials":2038,"activeCount":101},[],{"trials":2040,"activeCount":101},[2041,2048],{"nctId":2042,"briefTitle":2043,"status":208,"phases":2044,"primaryCompletion":1429,"completion":1429,"start":640,"enrollment":1079,"conditions":2045,"interventions":2047},"NCT01748097","Intravenous Bicarbonate To Verify The Correct Position of IV Catheters in Oncological Patients Oncological Patients Receiving Chemotherapy",[90,91],[2046],"Detection of the Correct Position of Intravenous Line",[647],{"nctId":637,"briefTitle":638,"status":208,"phases":2049,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":2050,"interventions":2051},[90,91],[644,645],[647,648,617],{"trials":2053,"activeCount":101},[],{"trials":2055,"activeCount":101},[],{"intervention":2057,"totalTrials":97,"cells":2058},"tranexamic acid",{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2079,"NA":2081},{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[],{"trials":2064,"activeCount":101},[],{"trials":2066,"activeCount":101},[2067],{"nctId":2068,"briefTitle":2069,"status":762,"phases":2070,"primaryCompletion":2071,"completion":2071,"start":2072,"enrollment":2073,"conditions":2074,"interventions":2078},"NCT03085394","Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery",[91],"2022-11-21","2017-09-01",152,[2075,2076,2077],"Intra-Operative Injury - Other","Post Operative Hemorrhage","Tranexamic Acid",[2057],{"trials":2080,"activeCount":101},[],{"trials":2082,"activeCount":101},[],{"intervention":2084,"totalTrials":97,"cells":2085},"raloxifene",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2102,"NA":2104},{"trials":2087,"activeCount":101},[],{"trials":2089,"activeCount":101},[],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":101},[2094],{"nctId":2095,"briefTitle":2096,"status":208,"phases":2097,"primaryCompletion":640,"completion":2098,"start":2011,"enrollment":2099,"conditions":2100,"interventions":2101},"NCT01280305","Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder",[91],"2013-03",200,[15,734],[2084],{"trials":2103,"activeCount":101},[],{"trials":2105,"activeCount":101},[],{"intervention":2107,"totalTrials":97,"cells":2108},"Kineret",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2125,"NA":2127},{"trials":2110,"activeCount":101},[],{"trials":2112,"activeCount":101},[],{"trials":2114,"activeCount":101},[],{"trials":2116,"activeCount":101},[2117],{"nctId":2118,"briefTitle":2119,"status":607,"phases":2120,"primaryCompletion":1165,"completion":1247,"start":2121,"enrollment":1123,"conditions":2122,"interventions":2124},"NCT01705756","Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever",[91],"2012-11",[2123],"Familial Mediterranean Fever",[2107],{"trials":2126,"activeCount":101},[],{"trials":2128,"activeCount":101},[],{"intervention":2130,"totalTrials":97,"cells":2131},"mRNA1273 vaccine",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2148,"NA":2150},{"trials":2133,"activeCount":101},[],{"trials":2135,"activeCount":101},[],{"trials":2137,"activeCount":101},[],{"trials":2139,"activeCount":101},[2140],{"nctId":2141,"briefTitle":2142,"status":208,"phases":2143,"primaryCompletion":2144,"completion":2144,"start":2145,"enrollment":1406,"conditions":2146,"interventions":2147},"NCT05230953","Fourth COVID-19 Vaccine Dose- mRNA1273",[91],"2024-07-04","2022-01-05",[1408],[2130],{"trials":2149,"activeCount":101},[],{"trials":2151,"activeCount":101},[],{"intervention":2153,"totalTrials":97,"cells":2154},"Caffeine",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2173,"NA":2175},{"trials":2156,"activeCount":101},[],{"trials":2158,"activeCount":101},[],{"trials":2160,"activeCount":101},[],{"trials":2162,"activeCount":101},[2163],{"nctId":2164,"briefTitle":2165,"status":607,"phases":2166,"primaryCompletion":2167,"completion":730,"start":2168,"enrollment":2169,"conditions":2170,"interventions":2172},"NCT00564824","The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease",[91],"2009-09","2007-11",80,[2171],"Coronary Disease",[2153],{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":101},[],{"intervention":2178,"totalTrials":97,"cells":2179},"prednisone - oral corticosteroid 1mg\u002Fkg\u002FD for 1 week",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2197,"NA":2199},{"trials":2181,"activeCount":101},[],{"trials":2183,"activeCount":101},[],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[2188],{"nctId":2189,"briefTitle":2190,"status":208,"phases":2191,"completion":2192,"start":2193,"enrollment":531,"conditions":2194,"interventions":2196},"NCT00416143","Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss",[90,91],"2008-12","2006-06",[2195],"Sudden Loss of Hearing",[2178],{"trials":2198,"activeCount":101},[],{"trials":2200,"activeCount":101},[],{"intervention":2202,"totalTrials":97,"cells":2203},"clomiphene citrate treatment",{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2220,"NA":2222},{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"trials":2209,"activeCount":101},[],{"trials":2211,"activeCount":101},[2212],{"nctId":2213,"briefTitle":2214,"status":208,"phases":2215,"primaryCompletion":2216,"completion":2217,"start":211,"enrollment":469,"conditions":2218,"interventions":2219},"NCT02255578","Endobarrier Treatment in Women With PCOS",[91],"2017-09","2018-09",[511],[2202],{"trials":2221,"activeCount":101},[],{"trials":2223,"activeCount":101},[],{"intervention":2225,"totalTrials":97,"cells":2226},"CAR-T CD19",{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2233,"PHASE4":2245,"NA":2247},{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"trials":2232,"activeCount":101},[],{"trials":2234,"activeCount":101},[2235],{"nctId":2236,"briefTitle":2237,"status":208,"phases":2238,"primaryCompletion":2239,"completion":2239,"start":2240,"enrollment":2241,"conditions":2242,"interventions":2244},"NCT04257175","CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression",[90,91],"2024-12-01","2020-02-18",10,[2243],"Acute Myeloid Leukemia",[2225],{"trials":2246,"activeCount":101},[],{"trials":2248,"activeCount":101},[],{"intervention":2250,"totalTrials":97,"cells":2251},"Levofloxacin",{"EARLY_PHASE1":2252,"PHASE1":2254,"PHASE2":2256,"PHASE3":2258,"PHASE4":2270,"NA":2272},{"trials":2253,"activeCount":101},[],{"trials":2255,"activeCount":101},[],{"trials":2257,"activeCount":101},[],{"trials":2259,"activeCount":101},[2260],{"nctId":2261,"briefTitle":2262,"status":607,"phases":2263,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":2266,"conditions":2267,"interventions":2269},"NCT02981615","Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients",[91],"2022-07-30","2017-08-01",67,[2268],"Prevention",[2250],{"trials":2271,"activeCount":101},[],{"trials":2273,"activeCount":101},[],{"intervention":2275,"totalTrials":97,"cells":2276},"T cell vaccination",{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2283,"PHASE4":2293,"NA":2295},{"trials":2278,"activeCount":101},[],{"trials":2280,"activeCount":101},[],{"trials":2282,"activeCount":101},[],{"trials":2284,"activeCount":101},[2285],{"nctId":2286,"briefTitle":2287,"status":208,"phases":2288,"completion":2289,"start":2290,"enrollment":2169,"conditions":2291,"interventions":2292},"NCT00228228","TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis",[91],"2006-12","2002-05",[24],[2275],{"trials":2294,"activeCount":101},[],{"trials":2296,"activeCount":101},[],{"intervention":2015,"totalTrials":97,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2311,"NA":2313},{"trials":2300,"activeCount":101},[],{"trials":2302,"activeCount":101},[],{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":101},[2307],{"nctId":2006,"briefTitle":2007,"status":208,"phases":2308,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":2012,"conditions":2309,"interventions":2310},[91],[15,734],[1995,2015,2016],{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[],{"intervention":2016,"totalTrials":97,"cells":2316},{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2329,"NA":2331},{"trials":2318,"activeCount":101},[],{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[2325],{"nctId":2006,"briefTitle":2007,"status":208,"phases":2326,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":2012,"conditions":2327,"interventions":2328},[91],[15,734],[1995,2015,2016],{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":101},[],{"intervention":2334,"totalTrials":97,"cells":2335},"Dunaliella",{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2352,"NA":2354},{"trials":2337,"activeCount":101},[],{"trials":2339,"activeCount":101},[],{"trials":2341,"activeCount":101},[],{"trials":2343,"activeCount":101},[2344],{"nctId":2345,"briefTitle":2346,"status":607,"phases":2347,"completion":2289,"start":2348,"enrollment":469,"conditions":2349,"interventions":2351},"NCT00156169","The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.",[91],"2001-05",[2350],"Low HDL Cholesterol",[2334],{"trials":2353,"activeCount":101},[],{"trials":2355,"activeCount":101},[],{"intervention":2357,"totalTrials":97,"cells":2358},"Propranolol and Etodolac",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2374,"NA":2376},{"trials":2360,"activeCount":101},[],{"trials":2362,"activeCount":101},[],{"trials":2364,"activeCount":101},[],{"trials":2366,"activeCount":101},[2367],{"nctId":2368,"briefTitle":2369,"status":208,"phases":2370,"primaryCompletion":227,"completion":227,"start":730,"enrollment":2012,"conditions":2371,"interventions":2373},"NCT00888797","β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence",[91],[2372],"Colorectal Neoplasms",[2357],{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":101},[],{"intervention":2026,"totalTrials":97,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":101},[],{"trials":2383,"activeCount":101},[],{"trials":2385,"activeCount":101},[],{"trials":2387,"activeCount":101},[2388],{"nctId":2018,"briefTitle":2019,"status":208,"phases":2389,"primaryCompletion":2011,"completion":2021,"start":1010,"enrollment":444,"conditions":2390,"interventions":2391},[91],[2023],[2025,2026],{"trials":2393,"activeCount":101},[],{"trials":2395,"activeCount":101},[],{"intervention":2397,"totalTrials":97,"cells":2398},"Magnesium Oxide",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2405,"PHASE4":2418,"NA":2420},{"trials":2400,"activeCount":101},[],{"trials":2402,"activeCount":101},[],{"trials":2404,"activeCount":101},[],{"trials":2406,"activeCount":101},[2407],{"nctId":2408,"briefTitle":2409,"status":208,"phases":2410,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":2414,"conditions":2415,"interventions":2417},"NCT03840226","The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients",[91],"2026-01-01","2026-03-01","2019-08-25",320,[2416,659],"Magnesium Deficiency",[2397],{"trials":2419,"activeCount":101},[],{"trials":2421,"activeCount":101},[],{"intervention":2423,"totalTrials":97,"cells":2424},"sitagliptin",{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2442,"NA":2444},{"trials":2426,"activeCount":101},[],{"trials":2428,"activeCount":101},[],{"trials":2430,"activeCount":101},[],{"trials":2432,"activeCount":101},[2433],{"nctId":2434,"briefTitle":2435,"status":607,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":444,"conditions":2439,"interventions":2441},"NCT00425490","Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus",[91],"2009-07","2007-01",[2440],"Diabetes Mellitus Type 2",[2423],{"trials":2443,"activeCount":101},[],{"trials":2445,"activeCount":101},[],{"intervention":2447,"totalTrials":97,"cells":2448},"Idazoxan",{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2455,"PHASE4":2463,"NA":2465},{"trials":2450,"activeCount":101},[],{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[2457],{"nctId":2458,"briefTitle":2459,"status":794,"phases":2460,"conditions":2461,"interventions":2462},"NCT00294944","The Effectiveness of Idazoxan in Treating TRD",[91],[29],[2447],{"trials":2464,"activeCount":101},[],{"trials":2466,"activeCount":101},[],{"intervention":2468,"totalTrials":97,"cells":2469},"ibritumomab tiuxetan",{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2474,"PHASE3":2476,"PHASE4":2486,"NA":2488},{"trials":2471,"activeCount":101},[],{"trials":2473,"activeCount":101},[],{"trials":2475,"activeCount":101},[],{"trials":2477,"activeCount":101},[2478],{"nctId":2479,"briefTitle":2480,"status":607,"phases":2481,"primaryCompletion":1053,"completion":1053,"start":2482,"enrollment":531,"conditions":2483,"interventions":2485},"NCT00491491","Zevalin-beam for Aggressive Lymphoma",[91],"2007-06",[2484],"Non-Hodgkin's Lymphoma",[2468],{"trials":2487,"activeCount":101},[],{"trials":2489,"activeCount":101},[],{"intervention":648,"totalTrials":97,"cells":2491},{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2498,"PHASE4":2504,"NA":2506},{"trials":2493,"activeCount":101},[],{"trials":2495,"activeCount":101},[],{"trials":2497,"activeCount":101},[],{"trials":2499,"activeCount":101},[2500],{"nctId":637,"briefTitle":638,"status":208,"phases":2501,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":2502,"interventions":2503},[90,91],[644,645],[647,648,617],{"trials":2505,"activeCount":101},[],{"trials":2507,"activeCount":101},[],{"intervention":2509,"totalTrials":97,"cells":2510},"Alga Dunaliella Bardawil",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2517,"PHASE4":2526,"NA":2528},{"trials":2512,"activeCount":101},[],{"trials":2514,"activeCount":101},[],{"trials":2516,"activeCount":101},[],{"trials":2518,"activeCount":101},[2519],{"nctId":2520,"briefTitle":2521,"status":794,"phases":2522,"primaryCompletion":245,"completion":1430,"start":730,"enrollment":101,"conditions":2523,"interventions":2525},"NCT01121081","The Effect of Algae Dunaliella Bardawil on Psoriasis (2)",[91],[2524],"Psoriasis",[2509],{"trials":2527,"activeCount":101},[],{"trials":2529,"activeCount":101},[],{"intervention":2531,"totalTrials":97,"cells":2532},"ibuprofen",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2539,"PHASE4":2549,"NA":2551},{"trials":2534,"activeCount":101},[],{"trials":2536,"activeCount":101},[],{"trials":2538,"activeCount":101},[],{"trials":2540,"activeCount":101},[2541],{"nctId":2542,"briefTitle":2543,"status":607,"phases":2544,"primaryCompletion":627,"completion":627,"start":2545,"enrollment":824,"conditions":2546,"interventions":2548},"NCT00997074","Efficacy Study of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion",[91],"2009-10",[2547,32],"Pain",[2531],{"trials":2550,"activeCount":101},[],{"trials":2552,"activeCount":101},[],{"intervention":2554,"totalTrials":97,"cells":2555},"Pegylated Interferon and Imatinib",{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2573,"NA":2575},{"trials":2557,"activeCount":101},[],{"trials":2559,"activeCount":101},[],{"trials":2561,"activeCount":101},[],{"trials":2563,"activeCount":101},[2564],{"nctId":2565,"briefTitle":2566,"status":208,"phases":2567,"start":2568,"enrollment":2569,"conditions":2570,"interventions":2572},"NCT00297570","Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy",[91],"2006-02",90,[2571],"Leukemia, Myeloid, Philadelphia-Positive",[2554],{"trials":2574,"activeCount":101},[],{"trials":2576,"activeCount":101},[],{"intervention":2578,"totalTrials":97,"cells":2579},"5-aminosalicylic acid",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2586,"PHASE4":2596,"NA":2598},{"trials":2581,"activeCount":101},[],{"trials":2583,"activeCount":101},[],{"trials":2585,"activeCount":101},[],{"trials":2587,"activeCount":101},[2588],{"nctId":2589,"briefTitle":2590,"status":607,"phases":2591,"primaryCompletion":211,"completion":2592,"start":2593,"enrollment":469,"conditions":2594,"interventions":2595},"NCT01320436","Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis",[91],"2014-10","2011-07",[1802],[2578],{"trials":2597,"activeCount":101},[],{"trials":2599,"activeCount":101},[],{"intervention":2601,"totalTrials":97,"cells":2602},"hydroxychloroquine in combination with camostat mesylate",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2623,"NA":2625},{"trials":2604,"activeCount":101},[],{"trials":2606,"activeCount":101},[],{"trials":2608,"activeCount":101},[],{"trials":2610,"activeCount":101},[2611],{"nctId":2612,"briefTitle":2613,"status":208,"phases":2614,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2621},"NCT04355052","Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus",[91],"2020-10-11","2020-12-11","2020-04-11",250,[2620],"COVID - 19",[2601,2622],"Hydroxychloroquine in combination of Azithromycin",{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[],{"intervention":2622,"totalTrials":97,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2641,"NA":2643},{"trials":2630,"activeCount":101},[],{"trials":2632,"activeCount":101},[],{"trials":2634,"activeCount":101},[],{"trials":2636,"activeCount":101},[2637],{"nctId":2612,"briefTitle":2613,"status":208,"phases":2638,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":2639,"interventions":2640},[91],[2620],[2601,2622],{"trials":2642,"activeCount":101},[],{"trials":2644,"activeCount":101},[],{"intervention":2646,"totalTrials":97,"cells":2647},"clopidogrel",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2664,"NA":2666},{"trials":2649,"activeCount":101},[],{"trials":2651,"activeCount":101},[],{"trials":2653,"activeCount":101},[],{"trials":2655,"activeCount":101},[2656],{"nctId":2657,"briefTitle":2658,"status":607,"phases":2659,"completion":2482,"start":2660,"enrollment":469,"conditions":2661,"interventions":2663},"NCT00444132","Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS",[91],"2005-03",[2662],"Clopidogrel Non-Responsiveness",[2646],{"trials":2665,"activeCount":101},[],{"trials":2667,"activeCount":101},[],{"intervention":2669,"totalTrials":97,"cells":2670},"plasma rich with WNV neutralizing antibodies",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2677,"PHASE4":2690,"NA":2692},{"trials":2672,"activeCount":101},[],{"trials":2674,"activeCount":101},[],{"trials":2676,"activeCount":101},[],{"trials":2678,"activeCount":101},[2679],{"nctId":2680,"briefTitle":2681,"status":607,"phases":2682,"primaryCompletion":2683,"completion":2684,"start":2144,"enrollment":2099,"conditions":2685,"interventions":2688},"NCT06590207","Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study",[91],"2025-01-31","2025-03-30",[2686,2687],"West Nile Fever With Neurologic Manifestation (Diagnosis)","West Nile Fever Without Complications",[2669,2689],"Saline",{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[],{"intervention":2689,"totalTrials":97,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2708,"NA":2710},{"trials":2697,"activeCount":101},[],{"trials":2699,"activeCount":101},[],{"trials":2701,"activeCount":101},[],{"trials":2703,"activeCount":101},[2704],{"nctId":2680,"briefTitle":2681,"status":607,"phases":2705,"primaryCompletion":2683,"completion":2684,"start":2144,"enrollment":2099,"conditions":2706,"interventions":2707},[91],[2686,2687],[2669,2689],{"trials":2709,"activeCount":101},[],{"trials":2711,"activeCount":101},[],{"intervention":2713,"totalTrials":97,"cells":2714},"clopidogrel by chewing",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2733,"NA":2735},{"trials":2716,"activeCount":101},[],{"trials":2718,"activeCount":101},[],{"trials":2720,"activeCount":101},[],{"trials":2722,"activeCount":101},[2723],{"nctId":2724,"briefTitle":2725,"status":208,"phases":2726,"primaryCompletion":2727,"completion":246,"start":2728,"enrollment":444,"conditions":2729,"interventions":2732},"NCT00889044","Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI",[91],"2010-12","2009-04",[2730,2731],"Platlet Aggregation","Major Bleeding Outcomes",[2713],{"trials":2734,"activeCount":101},[],{"trials":2736,"activeCount":101},[],{"intervention":2738,"totalTrials":574,"cells":2739},"Fludarabine",{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2785,"PHASE4":2787,"NA":2789},{"trials":2741,"activeCount":101},[],{"trials":2743,"activeCount":101},[],{"trials":2745,"activeCount":101},[2746,2759,2770],{"nctId":2747,"briefTitle":2748,"status":208,"phases":2749,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":2754,"interventions":2756},"NCT03412526","Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian",[90],"2021-02-01","2022-02-01","2018-01-21",15,[2755],"Metastatic Ovarian Cancer",[2738,2757,2758],"TIL administration","IL-2",{"nctId":2760,"briefTitle":2761,"status":208,"phases":2762,"primaryCompletion":2239,"completion":2763,"start":2764,"enrollment":264,"conditions":2765,"interventions":2767},"NCT04989335","Bisantrene Combination for Resistant AML",[90],"2025-12-01","2021-08-02",[2766],"Myelogenous Leukemia, Acute",[2768,2738,2769],"Bisantrene","Clofarabine",{"nctId":2771,"briefTitle":2772,"status":208,"phases":2773,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":2777,"interventions":2779},"NCT03166397","Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients",[90],"2025-01-01","2026-06-01","2017-06-05",[2778],"Malignant Melanoma Stage IV",[2738,2780,2781,2758,2782,2783,2784],"Cyclophosphamide","TIL","Nivolumab","Ipilimumab","FMT Protocol",{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[],{"intervention":2792,"totalTrials":483,"cells":2793},"Thiotepa",{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2795,"activeCount":101},[],{"trials":2797,"activeCount":101},[],{"trials":2799,"activeCount":101},[2800,2812],{"nctId":2801,"briefTitle":2802,"status":208,"phases":2803,"primaryCompletion":2804,"completion":2805,"start":2806,"enrollment":248,"conditions":2807,"interventions":2811},"NCT02507479","Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies",[90],"2017-07","2019-07","2015-09",[2808,2809,2810,307],"Non Hodgkin Lymphoma","Hodgkin Lymphoma","Chronic Lymphocytic Leukemia",[2792],{"nctId":2813,"briefTitle":2814,"status":607,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":469,"conditions":2818,"interventions":2820},"NCT03346096","TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma",[90],"2024-06-30","2018-10-09",[2819],"Malignant Lymphoma",[2792],{"trials":2822,"activeCount":101},[],{"trials":2824,"activeCount":101},[],{"trials":2826,"activeCount":101},[],{"intervention":2780,"totalTrials":483,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"trials":2834,"activeCount":101},[2835,2844],{"nctId":2836,"briefTitle":2837,"status":208,"phases":2838,"primaryCompletion":2239,"completion":2239,"start":2839,"enrollment":444,"conditions":2840,"interventions":2842},"NCT03357159","Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation",[90],"2018-09-06",[2841],"Graft Versus Host Disease",[2780,2843],"anti-human T-lymphocyte immunoglobulin",{"nctId":2771,"briefTitle":2772,"status":208,"phases":2845,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":2846,"interventions":2847},[90],[2778],[2738,2780,2781,2758,2782,2783,2784],{"trials":2849,"activeCount":101},[],{"trials":2851,"activeCount":101},[],{"trials":2853,"activeCount":101},[],{"intervention":2768,"totalTrials":483,"cells":2855},{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2860,"PHASE3":2877,"PHASE4":2879,"NA":2881},{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":101},[],{"trials":2861,"activeCount":101},[2862,2873],{"nctId":2863,"briefTitle":2864,"status":607,"phases":2865,"primaryCompletion":2866,"completion":2867,"start":2868,"enrollment":2241,"conditions":2869,"interventions":2872},"NCT03820908","Bisantrene for Relapsed \u002FRefractory AML",[90],"2020-05-19","2020-07-22","2019-07-18",[2870,2871],"Acute Myelogenous Leukemia","Allogeneic Stem Cell Transplantation",[2768],{"nctId":2760,"briefTitle":2761,"status":208,"phases":2874,"primaryCompletion":2239,"completion":2763,"start":2764,"enrollment":264,"conditions":2875,"interventions":2876},[90],[2766],[2768,2738,2769],{"trials":2878,"activeCount":101},[],{"trials":2880,"activeCount":101},[],{"trials":2882,"activeCount":101},[],{"intervention":2758,"totalTrials":483,"cells":2884},{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2886,"activeCount":101},[],{"trials":2888,"activeCount":101},[],{"trials":2890,"activeCount":101},[2891,2895],{"nctId":2747,"briefTitle":2748,"status":208,"phases":2892,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":2893,"interventions":2894},[90],[2755],[2738,2757,2758],{"nctId":2771,"briefTitle":2772,"status":208,"phases":2896,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":2897,"interventions":2898},[90],[2778],[2738,2780,2781,2758,2782,2783,2784],{"trials":2900,"activeCount":101},[],{"trials":2902,"activeCount":101},[],{"trials":2904,"activeCount":101},[],{"intervention":2782,"totalTrials":483,"cells":2906},{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2921,"PHASE3":2927,"PHASE4":2929,"NA":2931},{"trials":2908,"activeCount":101},[],{"trials":2910,"activeCount":101},[2911],{"nctId":2912,"briefTitle":2913,"status":208,"phases":2914,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":2241,"conditions":2917,"interventions":2919},"NCT05088889","Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer",[89],"2024-07-01","2022-01-25",[2918],"Stage IV Pancreatic Cancer",[2782,2920],"ipilimumab",{"trials":2922,"activeCount":101},[2923],{"nctId":2771,"briefTitle":2772,"status":208,"phases":2924,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":2925,"interventions":2926},[90],[2778],[2738,2780,2781,2758,2782,2783,2784],{"trials":2928,"activeCount":101},[],{"trials":2930,"activeCount":101},[],{"trials":2932,"activeCount":101},[],{"intervention":2783,"totalTrials":483,"cells":2934},{"EARLY_PHASE1":2935,"PHASE1":2937,"PHASE2":2943,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2936,"activeCount":101},[],{"trials":2938,"activeCount":101},[2939],{"nctId":2912,"briefTitle":2913,"status":208,"phases":2940,"primaryCompletion":2915,"completion":2915,"start":2916,"enrollment":2241,"conditions":2941,"interventions":2942},[89],[2918],[2782,2920],{"trials":2944,"activeCount":101},[2945],{"nctId":2771,"briefTitle":2772,"status":208,"phases":2946,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":2947,"interventions":2948},[90],[2778],[2738,2780,2781,2758,2782,2783,2784],{"trials":2950,"activeCount":101},[],{"trials":2952,"activeCount":101},[],{"trials":2954,"activeCount":101},[],{"intervention":2843,"totalTrials":97,"cells":2956},{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2958,"activeCount":101},[],{"trials":2960,"activeCount":101},[],{"trials":2962,"activeCount":101},[2963],{"nctId":2836,"briefTitle":2837,"status":208,"phases":2964,"primaryCompletion":2239,"completion":2239,"start":2839,"enrollment":444,"conditions":2965,"interventions":2966},[90],[2841],[2780,2843],{"trials":2968,"activeCount":101},[],{"trials":2970,"activeCount":101},[],{"trials":2972,"activeCount":101},[],{"intervention":2974,"totalTrials":97,"cells":2975},"Adoptive cell transfer",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2977,"activeCount":101},[],{"trials":2979,"activeCount":101},[],{"trials":2981,"activeCount":101},[2982],{"nctId":2983,"briefTitle":2984,"status":762,"phases":2985,"primaryCompletion":2986,"completion":2987,"start":657,"enrollment":483,"conditions":2988,"interventions":2990},"NCT01988077","Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients",[90],"2016-05-20","2018-10-25",[2989],"A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response",[2974,2991],"Ipilimumab 5 MG\u002FML Injection [Yervoy]",{"trials":2993,"activeCount":101},[],{"trials":2995,"activeCount":101},[],{"trials":2997,"activeCount":101},[],{"intervention":2991,"totalTrials":97,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":101},[],{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[3006],{"nctId":2983,"briefTitle":2984,"status":762,"phases":3007,"primaryCompletion":2986,"completion":2987,"start":657,"enrollment":483,"conditions":3008,"interventions":3009},[90],[2989],[2974,2991],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[],{"trials":3015,"activeCount":101},[],{"intervention":3017,"totalTrials":97,"cells":3018},"Nilotinib",{"EARLY_PHASE1":3019,"PHASE1":3021,"PHASE2":3023,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3020,"activeCount":101},[],{"trials":3022,"activeCount":101},[],{"trials":3024,"activeCount":101},[3025],{"nctId":3026,"briefTitle":3027,"status":607,"phases":3028,"primaryCompletion":609,"completion":609,"start":2437,"enrollment":248,"conditions":3029,"interventions":3033},"NCT00750659","Nilotinib Pre and Post Allogeneic Stem Cell Transplantation",[90],[3030,3031,3032],"Chronic Myeloid Leukemia","Acute Lymphoblastic Leukemia","Stem Cell Transplantation",[3017],{"trials":3035,"activeCount":101},[],{"trials":3037,"activeCount":101},[],{"trials":3039,"activeCount":101},[],{"intervention":3041,"totalTrials":97,"cells":3042},"Lonquek",{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":101},[3049],{"nctId":3050,"briefTitle":3051,"status":208,"phases":3052,"primaryCompletion":493,"completion":3053,"start":3054,"enrollment":248,"conditions":3055,"interventions":3057},"NCT02488382","Lonquek for Autologous Stem Cell Mobilization",[89,90],"2020-07","2017-07-01",[3056,307],"Lymphoma",[3041],{"trials":3059,"activeCount":101},[],{"trials":3061,"activeCount":101},[],{"trials":3063,"activeCount":101},[],{"intervention":3065,"totalTrials":97,"cells":3066},"Autlogous UCB",{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3071,"PHASE3":3086,"PHASE4":3088,"NA":3090},{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[],{"trials":3072,"activeCount":101},[3073],{"nctId":3074,"briefTitle":3075,"status":208,"phases":3076,"primaryCompletion":3077,"completion":3078,"start":3079,"enrollment":531,"conditions":3080,"interventions":3085},"NCT03558269","Autologous Umbilical Cord Blood Treatment of Neonate With CHD",[89,90],"2021-05-01","2023-04-01","2019-02-01",[3081,3082,3083,3084],"Congenital Heart Disease","Brain Injuries","Low Cardiac Output Syndrome","Neonatal Disorder",[3065],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"intervention":3093,"totalTrials":97,"cells":3094},"Methotrexate",{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3109,"PHASE4":3111,"NA":3113},{"trials":3096,"activeCount":101},[],{"trials":3098,"activeCount":101},[],{"trials":3100,"activeCount":101},[3101],{"nctId":3102,"briefTitle":3103,"status":208,"phases":3104,"primaryCompletion":3105,"completion":3105,"start":3106,"enrollment":1079,"conditions":3107,"interventions":3108},"NCT03369795","Add-on Methotrexate for the Treatment of Schizophrenia",[90],"2020-01-01","2017-12-15",[15],[3093],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"intervention":3116,"totalTrials":97,"cells":3117},"OLAPARIB",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3132,"PHASE4":3134,"NA":3136},{"trials":3119,"activeCount":101},[],{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":101},[3124],{"nctId":3125,"briefTitle":3126,"status":607,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":919,"enrollment":248,"conditions":3129,"interventions":3131},"NCT02511223","Efficacy and Safety of PARPi to Treat Pancreatic Cancer",[90],"2021-04-18",[3130],"Pancreatic Cancer",[3116],{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[],{"trials":3137,"activeCount":101},[],{"intervention":3139,"totalTrials":97,"cells":3140},"Tridecanoic Acid",{"EARLY_PHASE1":3141,"PHASE1":3143,"PHASE2":3145,"PHASE3":3156,"PHASE4":3158,"NA":3160},{"trials":3142,"activeCount":101},[],{"trials":3144,"activeCount":101},[],{"trials":3146,"activeCount":101},[3147],{"nctId":3148,"briefTitle":3149,"status":208,"phases":3150,"primaryCompletion":3151,"completion":682,"start":3152,"enrollment":2241,"conditions":3153,"interventions":3155},"NCT03059160","Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.",[90],"2018-04-01","2017-04-01",[3154],"Rett Syndrome",[3139],{"trials":3157,"activeCount":101},[],{"trials":3159,"activeCount":101},[],{"trials":3161,"activeCount":101},[],{"intervention":3163,"totalTrials":97,"cells":3164},"Deferiprone",{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3181,"PHASE4":3183,"NA":3185},{"trials":3166,"activeCount":101},[],{"trials":3168,"activeCount":101},[],{"trials":3170,"activeCount":101},[3171],{"nctId":3172,"briefTitle":3173,"status":607,"phases":3174,"primaryCompletion":3175,"completion":3176,"start":584,"enrollment":11,"conditions":3177,"interventions":3180},"NCT02477631","Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients",[90],"2017-05","2018-06",[3178,3179],"Myelodysplastic Syndrome With Low-grade Lesions","Iron Overload Due to Repeated Red Blood Cell Transfusions",[3163],{"trials":3182,"activeCount":101},[],{"trials":3184,"activeCount":101},[],{"trials":3186,"activeCount":101},[],{"intervention":3188,"totalTrials":97,"cells":3189},"RAD001",{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3191,"activeCount":101},[],{"trials":3193,"activeCount":101},[],{"trials":3195,"activeCount":101},[3196],{"nctId":3197,"briefTitle":3198,"status":208,"phases":3199,"primaryCompletion":1010,"start":3200,"enrollment":2753,"conditions":3201,"interventions":3203},"NCT00657982","Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer",[90],"2008-04",[3202],"Prostate Cancer",[3188],{"trials":3205,"activeCount":101},[],{"trials":3207,"activeCount":101},[],{"trials":3209,"activeCount":101},[],{"intervention":3211,"totalTrials":97,"cells":3212},"treosulfan",{"EARLY_PHASE1":3213,"PHASE1":3215,"PHASE2":3217,"PHASE3":3226,"PHASE4":3228,"NA":3230},{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":101},[],{"trials":3218,"activeCount":101},[3219],{"nctId":3220,"briefTitle":3221,"status":208,"phases":3222,"primaryCompletion":3223,"completion":3223,"start":1010,"enrollment":8,"conditions":3224,"interventions":3225},"NCT01079013","Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies",[90],"2018-04",[2808,2809],[3211],{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[],{"trials":3231,"activeCount":101},[],{"intervention":3233,"totalTrials":97,"cells":3234},"mRNA-1273.214 Vaccine",{"EARLY_PHASE1":3235,"PHASE1":3237,"PHASE2":3239,"PHASE3":3255,"PHASE4":3257,"NA":3259},{"trials":3236,"activeCount":101},[],{"trials":3238,"activeCount":101},[],{"trials":3240,"activeCount":101},[3241],{"nctId":3242,"briefTitle":3243,"status":607,"phases":3244,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":3248,"interventions":3252},"NCT05383560","Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults",[90],"2024-01-31","2022-09-05",179,[1408,3249,3250,3251],"Immunogenicity","SARS CoV 2 Infection","COVID-19",[3233,3253,3254],"MRNA-1273 Vaccine","MRNA-1273.222 Vaccine",{"trials":3256,"activeCount":101},[],{"trials":3258,"activeCount":101},[],{"trials":3260,"activeCount":101},[],{"intervention":3253,"totalTrials":97,"cells":3262},{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3273,"PHASE4":3275,"NA":3277},{"trials":3264,"activeCount":101},[],{"trials":3266,"activeCount":101},[],{"trials":3268,"activeCount":101},[3269],{"nctId":3242,"briefTitle":3243,"status":607,"phases":3270,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":3271,"interventions":3272},[90],[1408,3249,3250,3251],[3233,3253,3254],{"trials":3274,"activeCount":101},[],{"trials":3276,"activeCount":101},[],{"trials":3278,"activeCount":101},[],{"intervention":3254,"totalTrials":97,"cells":3280},{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3291,"PHASE4":3293,"NA":3295},{"trials":3282,"activeCount":101},[],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":101},[3287],{"nctId":3242,"briefTitle":3243,"status":607,"phases":3288,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":3289,"interventions":3290},[90],[1408,3249,3250,3251],[3233,3253,3254],{"trials":3292,"activeCount":101},[],{"trials":3294,"activeCount":101},[],{"trials":3296,"activeCount":101},[],{"intervention":3298,"totalTrials":97,"cells":3299},"T-Cell Vaccination",{"EARLY_PHASE1":3300,"PHASE1":3302,"PHASE2":3304,"PHASE3":3314,"PHASE4":3316,"NA":3318},{"trials":3301,"activeCount":101},[],{"trials":3303,"activeCount":101},[],{"trials":3305,"activeCount":101},[3306],{"nctId":3307,"briefTitle":3308,"status":208,"phases":3309,"completion":3310,"start":3311,"enrollment":642,"conditions":3312,"interventions":3313},"NCT00220428","T-Cell Vaccination in Multiple Sclerosis (MS)",[89,90],"2007-12","1998-07",[24],[3298],{"trials":3315,"activeCount":101},[],{"trials":3317,"activeCount":101},[],{"trials":3319,"activeCount":101},[],{"intervention":3321,"totalTrials":97,"cells":3322},"Afatinib treatment",{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[3329],{"nctId":3330,"briefTitle":3331,"status":208,"phases":3332,"primaryCompletion":3333,"start":3334,"enrollment":642,"conditions":3335,"interventions":3337},"NCT01932229","An Open Label Study of BIBW 2992\u002FAfatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib",[90],"2015-01","2013-02",[3336],"NSCLC",[3321],{"trials":3339,"activeCount":101},[],{"trials":3341,"activeCount":101},[],{"trials":3343,"activeCount":101},[],{"intervention":2757,"totalTrials":97,"cells":3345},{"EARLY_PHASE1":3346,"PHASE1":3348,"PHASE2":3350,"PHASE3":3356,"PHASE4":3358,"NA":3360},{"trials":3347,"activeCount":101},[],{"trials":3349,"activeCount":101},[],{"trials":3351,"activeCount":101},[3352],{"nctId":2747,"briefTitle":2748,"status":208,"phases":3353,"primaryCompletion":2750,"completion":2751,"start":2752,"enrollment":2753,"conditions":3354,"interventions":3355},[90],[2755],[2738,2757,2758],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"intervention":3363,"totalTrials":97,"cells":3364},"Autologous umbilical cord blood",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3366,"activeCount":101},[],{"trials":3368,"activeCount":101},[],{"trials":3370,"activeCount":101},[3371],{"nctId":3372,"briefTitle":3373,"status":208,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":531,"conditions":3377,"interventions":3379},"NCT04243382","Treatment of Children With Autistic Spectrum Disorder With Autologous Umbilical Cord Blood, a Pilot Study",[90],"2024-12","2020-02-27",[3378],"Autistic Spectrum Disorder",[3363],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[],{"intervention":2769,"totalTrials":97,"cells":3387},{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3389,"activeCount":101},[],{"trials":3391,"activeCount":101},[],{"trials":3393,"activeCount":101},[3394],{"nctId":2760,"briefTitle":2761,"status":208,"phases":3395,"primaryCompletion":2239,"completion":2763,"start":2764,"enrollment":264,"conditions":3396,"interventions":3397},[90],[2766],[2768,2738,2769],{"trials":3399,"activeCount":101},[],{"trials":3401,"activeCount":101},[],{"trials":3403,"activeCount":101},[],{"intervention":3405,"totalTrials":97,"cells":3406},"Proleukin",{"EARLY_PHASE1":3407,"PHASE1":3409,"PHASE2":3411,"PHASE3":3423,"PHASE4":3425,"NA":3427},{"trials":3408,"activeCount":101},[],{"trials":3410,"activeCount":101},[],{"trials":3412,"activeCount":101},[3413],{"nctId":3414,"briefTitle":3415,"status":208,"phases":3416,"primaryCompletion":3417,"completion":3418,"start":3419,"enrollment":642,"conditions":3420,"interventions":3422},"NCT04383067","A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients",[90],"2022-06-01","2023-06-01","2020-05-12",[3421],"Metastatic Urothelial Carcinoma",[3405],{"trials":3424,"activeCount":101},[],{"trials":3426,"activeCount":101},[],{"trials":3428,"activeCount":101},[],{"intervention":3430,"totalTrials":97,"cells":3431},"Xiaflex",{"EARLY_PHASE1":3432,"PHASE1":3434,"PHASE2":3436,"PHASE3":3446,"PHASE4":3448,"NA":3450},{"trials":3433,"activeCount":101},[],{"trials":3435,"activeCount":101},[],{"trials":3437,"activeCount":101},[3438],{"nctId":3439,"briefTitle":3440,"status":208,"phases":3441,"primaryCompletion":717,"completion":3442,"start":2011,"enrollment":2241,"conditions":3443,"interventions":3445},"NCT01237964","Injectable Collagenase For Burns' Associated Contracture",[90],"2011-08",[3444],"Burn's Associated Contracture",[3430],{"trials":3447,"activeCount":101},[],{"trials":3449,"activeCount":101},[],{"trials":3451,"activeCount":101},[],{"intervention":3453,"totalTrials":97,"cells":3454},"Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin",{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3459,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3456,"activeCount":101},[],{"trials":3458,"activeCount":101},[],{"trials":3460,"activeCount":101},[3461],{"nctId":3462,"briefTitle":3463,"status":208,"phases":3464,"primaryCompletion":1430,"completion":3465,"start":245,"enrollment":3466,"conditions":3467,"interventions":3469},"NCT01272310","Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.",[89,90],"2013-07",36,[3468],"Chronic Hepatitis C",[3453],{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":101},[],{"trials":3475,"activeCount":101},[],{"intervention":3477,"totalTrials":97,"cells":3478},"Colchicine",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3483,"PHASE3":3494,"PHASE4":3496,"NA":3498},{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[],{"trials":3484,"activeCount":101},[3485],{"nctId":3486,"briefTitle":3487,"status":208,"phases":3488,"primaryCompletion":3489,"completion":3489,"start":3490,"enrollment":8,"conditions":3491,"interventions":3493},"NCT02442921","Colchicine for Diabetic Nephropathy Trial",[89,90],"2019-04-30","2016-02-22",[3492],"Diabetic Nephropathies",[3477],{"trials":3495,"activeCount":101},[],{"trials":3497,"activeCount":101},[],{"trials":3499,"activeCount":101},[],{"intervention":3501,"totalTrials":97,"cells":3502},"Plerixafor",{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3504,"activeCount":101},[],{"trials":3506,"activeCount":101},[],{"trials":3508,"activeCount":101},[3509],{"nctId":3510,"briefTitle":3511,"status":607,"phases":3512,"primaryCompletion":1122,"completion":1122,"start":848,"enrollment":642,"conditions":3513,"interventions":3517},"NCT01164345","Mozobil for Autologous Stem Cell Mobilization",[90],[2484,3514,3515,3516],"Hodgkin's Lymphoma","Stem Cell Mobilization","Autologous Stem Cell Transplantation",[3501],{"trials":3519,"activeCount":101},[],{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[],{"intervention":3525,"totalTrials":97,"cells":3526},"Fermented Wheat germ extract",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3540,"PHASE4":3542,"NA":3544},{"trials":3528,"activeCount":101},[],{"trials":3530,"activeCount":101},[],{"trials":3532,"activeCount":101},[3533],{"nctId":3534,"briefTitle":3535,"status":208,"phases":3536,"primaryCompletion":246,"completion":2009,"start":2482,"enrollment":531,"conditions":3537,"interventions":3539},"NCT00411853","Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients",[90],[3538],"Hormone Refractory Prostate Cancer",[3525],{"trials":3541,"activeCount":101},[],{"trials":3543,"activeCount":101},[],{"trials":3545,"activeCount":101},[],{"intervention":3547,"totalTrials":97,"cells":3548},"CD19 CAR T cells",{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3550,"activeCount":101},[],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[3555],{"nctId":3556,"briefTitle":3557,"status":208,"phases":3558,"primaryCompletion":3559,"completion":3560,"start":3561,"enrollment":3562,"conditions":3563,"interventions":3566},"NCT02772198","T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies",[89,90],"2022-07","2022-11","2016-11",300,[3564,3565],"Acute Lymphoblastic Leukemia, B-precursor","Non-Hodgkin Lymphoma, B-cell",[3547],{"trials":3568,"activeCount":101},[],{"trials":3570,"activeCount":101},[],{"trials":3572,"activeCount":101},[],{"intervention":2781,"totalTrials":97,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3576,"activeCount":101},[],{"trials":3578,"activeCount":101},[],{"trials":3580,"activeCount":101},[3581],{"nctId":2771,"briefTitle":2772,"status":208,"phases":3582,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":3583,"interventions":3584},[90],[2778],[2738,2780,2781,2758,2782,2783,2784],{"trials":3586,"activeCount":101},[],{"trials":3588,"activeCount":101},[],{"trials":3590,"activeCount":101},[],{"intervention":2784,"totalTrials":97,"cells":3592},{"EARLY_PHASE1":3593,"PHASE1":3595,"PHASE2":3597,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3594,"activeCount":101},[],{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":101},[3599],{"nctId":2771,"briefTitle":2772,"status":208,"phases":3600,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":444,"conditions":3601,"interventions":3602},[90],[2778],[2738,2780,2781,2758,2782,2783,2784],{"trials":3604,"activeCount":101},[],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[],{"intervention":3610,"totalTrials":97,"cells":3611},"BL-8040",{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3613,"activeCount":101},[],{"trials":3615,"activeCount":101},[],{"trials":3617,"activeCount":101},[3618],{"nctId":3619,"briefTitle":3620,"status":794,"phases":3621,"primaryCompletion":3561,"completion":3622,"start":1540,"enrollment":101,"conditions":3623,"interventions":3624},"NCT02115672","Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia",[89,90],"2018-11",[3030],[3610],{"trials":3626,"activeCount":101},[],{"trials":3628,"activeCount":101},[],{"trials":3630,"activeCount":101},[],{"intervention":3632,"totalTrials":97,"cells":3633},"D-serine",{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3648,"PHASE4":3650,"NA":3652},{"trials":3635,"activeCount":101},[],{"trials":3637,"activeCount":101},[],{"trials":3639,"activeCount":101},[3640],{"nctId":3641,"briefTitle":3642,"status":208,"phases":3643,"completion":3644,"start":3645,"enrollment":2099,"conditions":3646,"interventions":3647},"NCT00138775","Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia",[90],"2007-10","2004-10",[15,734],[3632],{"trials":3649,"activeCount":101},[],{"trials":3651,"activeCount":101},[],{"trials":3653,"activeCount":101},[],{"intervention":3655,"totalTrials":97,"cells":3656},"TevaGastrim",{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3671,"PHASE4":3673,"NA":3675},{"trials":3658,"activeCount":101},[],{"trials":3660,"activeCount":101},[],{"trials":3662,"activeCount":101},[3663],{"nctId":3664,"briefTitle":3665,"status":607,"phases":3666,"primaryCompletion":609,"completion":609,"start":3667,"enrollment":248,"conditions":3668,"interventions":3670},"NCT01542944","TevaGastrim for Stem Cell Mobilization Sibling Donors",[90],"2012-02",[2243,3669],"Myelodysplastic Syndrome",[3655],{"trials":3672,"activeCount":101},[],{"trials":3674,"activeCount":101},[],{"trials":3676,"activeCount":101},[],{"intervention":631,"totalTrials":97,"cells":3678},{"EARLY_PHASE1":3679,"PHASE1":3681,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3693},{"trials":3680,"activeCount":101},[],{"trials":3682,"activeCount":101},[3683],{"nctId":624,"briefTitle":625,"status":208,"phases":3684,"primaryCompletion":246,"completion":246,"start":627,"enrollment":444,"conditions":3685,"interventions":3686},[89],[629],[631,617],{"trials":3688,"activeCount":101},[],{"trials":3690,"activeCount":101},[],{"trials":3692,"activeCount":101},[],{"trials":3694,"activeCount":101},[],{"intervention":3696,"totalTrials":97,"cells":3697},"standard dose capecitabine",{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3710,"PHASE3":3712,"PHASE4":3714,"NA":3716},{"trials":3699,"activeCount":101},[],{"trials":3701,"activeCount":101},[3702],{"nctId":3703,"briefTitle":3704,"status":208,"phases":3705,"primaryCompletion":694,"completion":2216,"start":1165,"enrollment":1317,"conditions":3706,"interventions":3708},"NCT02137356","Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer",[89],[3707],"Rectal Neoplasms",[3696,3709],"dose-escalated selinexor treatment",{"trials":3711,"activeCount":101},[],{"trials":3713,"activeCount":101},[],{"trials":3715,"activeCount":101},[],{"trials":3717,"activeCount":101},[],{"intervention":3709,"totalTrials":97,"cells":3719},{"EARLY_PHASE1":3720,"PHASE1":3722,"PHASE2":3728,"PHASE3":3730,"PHASE4":3732,"NA":3734},{"trials":3721,"activeCount":101},[],{"trials":3723,"activeCount":101},[3724],{"nctId":3703,"briefTitle":3704,"status":208,"phases":3725,"primaryCompletion":694,"completion":2216,"start":1165,"enrollment":1317,"conditions":3726,"interventions":3727},[89],[3707],[3696,3709],{"trials":3729,"activeCount":101},[],{"trials":3731,"activeCount":101},[],{"trials":3733,"activeCount":101},[],{"trials":3735,"activeCount":101},[],{"intervention":3737,"totalTrials":97,"cells":3738},"Nivolumab Injection [Opdivo]",{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3762},{"trials":3740,"activeCount":101},[],{"trials":3742,"activeCount":101},[3743],{"nctId":3744,"briefTitle":3745,"status":607,"phases":3746,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":11,"conditions":3750,"interventions":3753},"NCT03507699","Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer",[89],"2021-08-18","2022-05-25","2018-12-15",[3751,3752],"Colorectal Neoplasms Malignant","Liver Metastases",[3737,3754,3755],"Ipilimumab Injection [Yervoy]","CMP-001",{"trials":3757,"activeCount":101},[],{"trials":3759,"activeCount":101},[],{"trials":3761,"activeCount":101},[],{"trials":3763,"activeCount":101},[],{"intervention":3754,"totalTrials":97,"cells":3765},{"EARLY_PHASE1":3766,"PHASE1":3768,"PHASE2":3774,"PHASE3":3776,"PHASE4":3778,"NA":3780},{"trials":3767,"activeCount":101},[],{"trials":3769,"activeCount":101},[3770],{"nctId":3744,"briefTitle":3745,"status":607,"phases":3771,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":11,"conditions":3772,"interventions":3773},[89],[3751,3752],[3737,3754,3755],{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[],{"trials":3779,"activeCount":101},[],{"trials":3781,"activeCount":101},[],{"intervention":3755,"totalTrials":97,"cells":3783},{"EARLY_PHASE1":3784,"PHASE1":3786,"PHASE2":3792,"PHASE3":3794,"PHASE4":3796,"NA":3798},{"trials":3785,"activeCount":101},[],{"trials":3787,"activeCount":101},[3788],{"nctId":3744,"briefTitle":3745,"status":607,"phases":3789,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":11,"conditions":3790,"interventions":3791},[89],[3751,3752],[3737,3754,3755],{"trials":3793,"activeCount":101},[],{"trials":3795,"activeCount":101},[],{"trials":3797,"activeCount":101},[],{"trials":3799,"activeCount":101},[],{"intervention":3801,"totalTrials":97,"cells":3802},"CBD",{"EARLY_PHASE1":3803,"PHASE1":3805,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3804,"activeCount":101},[],{"trials":3806,"activeCount":101},[3807],{"nctId":3808,"briefTitle":3809,"status":208,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3813,"enrollment":469,"conditions":3814,"interventions":3816},"NCT04686539","Synthetic CBD as a Therapy for COVID-19",[89],"2021-11","2022-01","2021-01-20",[3815,3801],"Covid19",[3801],{"trials":3818,"activeCount":101},[],{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"trials":3824,"activeCount":101},[],{"intervention":3826,"totalTrials":97,"cells":3827},"GTA: Glyceryltriacetate",{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3842,"PHASE3":3844,"PHASE4":3846,"NA":3848},{"trials":3829,"activeCount":101},[],{"trials":3831,"activeCount":101},[3832],{"nctId":3833,"briefTitle":3834,"status":208,"phases":3835,"completion":3836,"start":3837,"enrollment":766,"conditions":3838,"interventions":3841},"NCT00278707","GTA-Glyceryltriacetate for Canavan Disease",[89],"2006-07","2006-01",[3839,3840],"Infantile Canavan Disease","Deficiency Disease, Aspartoacylase",[3826],{"trials":3843,"activeCount":101},[],{"trials":3845,"activeCount":101},[],{"trials":3847,"activeCount":101},[],{"trials":3849,"activeCount":101},[],{"intervention":3851,"totalTrials":97,"cells":3852},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3868,"PHASE3":3870,"PHASE4":3872,"NA":3874},{"trials":3854,"activeCount":101},[],{"trials":3856,"activeCount":101},[3857],{"nctId":3858,"briefTitle":3859,"status":208,"phases":3860,"primaryCompletion":3861,"completion":3862,"start":3863,"enrollment":197,"conditions":3864,"interventions":3867},"NCT03214289","Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease",[89],"2019-07-20","2019-12-20","2017-07-12",[3865,3866,3851],"Stem Cell Transplant Complications","Graft Versus Host Disease, Acute",[3851],{"trials":3869,"activeCount":101},[],{"trials":3871,"activeCount":101},[],{"trials":3873,"activeCount":101},[],{"trials":3875,"activeCount":101},[],{"intervention":3877,"totalTrials":97,"cells":3878},"ABMD-MSC",{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3893,"PHASE3":3895,"PHASE4":3897,"NA":3899},{"trials":3880,"activeCount":101},[],{"trials":3882,"activeCount":101},[3883],{"nctId":3884,"briefTitle":3885,"status":208,"phases":3886,"primaryCompletion":3887,"completion":1009,"start":1988,"enrollment":3888,"conditions":3889,"interventions":3892},"NCT01686139","Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers",[89],"2017-03",12,[3890,3891],"Type I Diabetes Mellitus With Ulcer","Type II Diabetes Mellitus With Ulcer",[3877],{"trials":3894,"activeCount":101},[],{"trials":3896,"activeCount":101},[],{"trials":3898,"activeCount":101},[],{"trials":3900,"activeCount":101},[],{"intervention":3902,"totalTrials":97,"cells":3903},"Ritalin",{"EARLY_PHASE1":3904,"PHASE1":3906,"PHASE2":3918,"PHASE3":3920,"PHASE4":3922,"NA":3924},{"trials":3905,"activeCount":101},[],{"trials":3907,"activeCount":101},[3908],{"nctId":3909,"briefTitle":3910,"status":208,"phases":3911,"completion":3912,"start":3913,"enrollment":2169,"conditions":3914,"interventions":3917},"NCT00220493","Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients",[89],"2005-06","2003-06",[3915,3916],"Relapsing Remitting Multiple Sclerosis","Multiple Sclerosis, Chronic Progressive",[3902],{"trials":3919,"activeCount":101},[],{"trials":3921,"activeCount":101},[],{"trials":3923,"activeCount":101},[],{"trials":3925,"activeCount":101},[],{"intervention":3927,"totalTrials":97,"cells":3928},"carfilzumib",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3941,"PHASE3":3943,"PHASE4":3945,"NA":3947},{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":101},[3933],{"nctId":3934,"briefTitle":3935,"status":208,"phases":3936,"primaryCompletion":3937,"completion":3937,"start":1540,"enrollment":444,"conditions":3938,"interventions":3940},"NCT01991301","Carfilzomib for the Prevention of Graft Versus Host Disease",[89],"2017-11",[3939],"Graft-versus-host Disease",[3927],{"trials":3942,"activeCount":101},[],{"trials":3944,"activeCount":101},[],{"trials":3946,"activeCount":101},[],{"trials":3948,"activeCount":101},[],{"intervention":3950,"totalTrials":97,"cells":3951},"Nitrous oxide",{"EARLY_PHASE1":3952,"PHASE1":3964,"PHASE2":3966,"PHASE3":3968,"PHASE4":3970,"NA":3972},{"trials":3953,"activeCount":101},[3954],{"nctId":3955,"briefTitle":3956,"status":208,"phases":3957,"primaryCompletion":3958,"completion":3375,"start":3959,"enrollment":531,"conditions":3960,"interventions":3962},"NCT05579288","Use of Nitrous Oxide for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Dilatation and Evacuation",[88],"2024-06","2022-12",[686,687,688,3961],"Nitrous Oxide",[3950,3963],"Oxygen",{"trials":3965,"activeCount":101},[],{"trials":3967,"activeCount":101},[],{"trials":3969,"activeCount":101},[],{"trials":3971,"activeCount":101},[],{"trials":3973,"activeCount":101},[],{"intervention":3963,"totalTrials":97,"cells":3975},{"EARLY_PHASE1":3976,"PHASE1":3982,"PHASE2":3984,"PHASE3":3986,"PHASE4":3988,"NA":3990},{"trials":3977,"activeCount":101},[3978],{"nctId":3955,"briefTitle":3956,"status":208,"phases":3979,"primaryCompletion":3958,"completion":3375,"start":3959,"enrollment":531,"conditions":3980,"interventions":3981},[88],[686,687,688,3961],[3950,3963],{"trials":3983,"activeCount":101},[],{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[],{"trials":3991,"activeCount":101},[],{"intervention":3993,"totalTrials":766,"cells":3994},"Escitalopram",{"EARLY_PHASE1":3995,"PHASE1":3997,"PHASE2":3999,"PHASE3":4001,"PHASE4":4003,"NA":4029},{"trials":3996,"activeCount":101},[],{"trials":3998,"activeCount":101},[],{"trials":4000,"activeCount":101},[],{"trials":4002,"activeCount":101},[],{"trials":4004,"activeCount":101},[4005,4013,4020],{"nctId":4006,"briefTitle":4007,"status":208,"phases":4008,"start":4009,"enrollment":8,"conditions":4010,"interventions":4012},"NCT00229333","Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia",[92],"2004-12",[4011],"Depressive Syndrome",[3993],{"nctId":4014,"briefTitle":4015,"status":208,"phases":4016,"start":4017,"enrollment":1123,"conditions":4018,"interventions":4019},"NCT00442481","Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder",[92],"2007-02",[29],[3993],{"nctId":4021,"briefTitle":4022,"status":208,"phases":4023,"primaryCompletion":4024,"completion":2545,"start":3200,"enrollment":444,"conditions":4025,"interventions":4028},"NCT00650897","Efficacy Study of Escitalopram for Depression in Patients With Diabetes",[92],"2009-06",[4026,4027],"Major Depression","Diabetes Mellitus",[3993],{"trials":4030,"activeCount":101},[4031,4040],{"nctId":4032,"briefTitle":4033,"status":208,"phases":4034,"primaryCompletion":246,"start":4035,"enrollment":531,"conditions":4036,"interventions":4038},"NCT00220480","A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression",[93],"2005-02",[4037],"Depressive Disorder, Major",[4039],"escitalopram",{"nctId":4041,"briefTitle":4042,"status":607,"phases":4043,"primaryCompletion":4044,"completion":4044,"start":3912,"enrollment":4045,"conditions":4046,"interventions":4048},"NCT00300313","PTSD Prevention Using Escitalopram",[93],"2009-05",450,[4047],"Post-traumatic Stress Disorder",[3993],{"intervention":772,"totalTrials":574,"cells":4050},{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4057,"PHASE4":4059,"NA":4065},{"trials":4052,"activeCount":101},[],{"trials":4054,"activeCount":101},[],{"trials":4056,"activeCount":101},[],{"trials":4058,"activeCount":101},[],{"trials":4060,"activeCount":101},[4061],{"nctId":760,"briefTitle":761,"status":762,"phases":4062,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":4063,"interventions":4064},[92],[768,769,770],[772,739],{"trials":4066,"activeCount":101},[4067,4074],{"nctId":4068,"briefTitle":4069,"status":208,"phases":4070,"primaryCompletion":1078,"completion":1009,"start":1165,"enrollment":305,"conditions":4071,"interventions":4073},"NCT02318017","Psychostimulants Effects on Brain Functional Connectivity in Youth With Attention Deficit Hyperactivity Disorder",[93],[4072],"Adhd",[772],{"nctId":4075,"briefTitle":4076,"status":208,"phases":4077,"primaryCompletion":4078,"completion":2216,"start":609,"enrollment":642,"conditions":4079,"interventions":4080},"NCT02704546","Methylphenidate (Ritalin®) Effect During Exposure to Exercise and Heat Stress in ADD\u002FADHD Treated Patients",[93],"2017-04",[772],[772],{"intervention":1932,"totalTrials":483,"cells":4082},{"EARLY_PHASE1":4083,"PHASE1":4085,"PHASE2":4087,"PHASE3":4089,"PHASE4":4091,"NA":4097},{"trials":4084,"activeCount":101},[],{"trials":4086,"activeCount":101},[],{"trials":4088,"activeCount":101},[],{"trials":4090,"activeCount":101},[],{"trials":4092,"activeCount":101},[4093],{"nctId":1926,"briefTitle":1927,"status":208,"phases":4094,"primaryCompletion":1078,"completion":227,"start":696,"enrollment":531,"conditions":4095,"interventions":4096},[92],[1930],[1932,1913],{"trials":4098,"activeCount":101},[4099],{"nctId":4100,"briefTitle":4101,"status":208,"phases":4102,"primaryCompletion":4103,"completion":695,"start":4104,"enrollment":2241,"conditions":4105,"interventions":4106},"NCT02219867","Ketamine Infusions for Major Depression Disorder",[93],"2016-01","2014-08",[4037],[1932],{"intervention":4108,"totalTrials":483,"cells":4109},"Glatiramer Acetate",{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4120,"PHASE3":4122,"PHASE4":4124,"NA":4126},{"trials":4111,"activeCount":101},[],{"trials":4113,"activeCount":101},[4114],{"nctId":4115,"briefTitle":4116,"status":208,"phases":4117,"primaryCompletion":211,"completion":1053,"start":1272,"enrollment":2241,"conditions":4118,"interventions":4119},"NCT02023424","An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome",[89],[3154],[4108],{"trials":4121,"activeCount":101},[],{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"trials":4127,"activeCount":101},[4128],{"nctId":4129,"briefTitle":4130,"status":208,"phases":4131,"start":4132,"enrollment":642,"conditions":4133,"interventions":4134},"NCT00331747","Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate",[93],"2006-05",[24],[4135],"Glatiramer acetate",{"intervention":4137,"totalTrials":483,"cells":4138},"Decapeptyl",{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4145,"PHASE4":4147,"NA":4149},{"trials":4140,"activeCount":101},[],{"trials":4142,"activeCount":101},[],{"trials":4144,"activeCount":101},[],{"trials":4146,"activeCount":101},[],{"trials":4148,"activeCount":101},[],{"trials":4150,"activeCount":101},[4151,4159],{"nctId":4152,"briefTitle":4153,"status":208,"phases":4154,"primaryCompletion":610,"completion":610,"start":1272,"enrollment":531,"conditions":4155,"interventions":4157},"NCT02144818","GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response",[93],[4156],"Women With Poor Ovarian Response",[4158,4137],"Ovitrel",{"nctId":4160,"briefTitle":4161,"status":607,"phases":4162,"primaryCompletion":4163,"completion":4163,"start":4164,"enrollment":2099,"conditions":4165,"interventions":4167},"NCT03660813","Follicle Size and Oocyte Development",[93],"2021-08-01","2018-07-01",[4166],"IVF Treatment",[4168,4137],"Ovitrelle",{"intervention":4170,"totalTrials":97,"cells":4171},"polyethylene glycol",{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4176,"PHASE3":4178,"PHASE4":4180,"NA":4182},{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":101},[],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[],{"trials":4183,"activeCount":101},[4184],{"nctId":4185,"briefTitle":4186,"status":762,"phases":4187,"primaryCompletion":4188,"completion":4188,"start":4189,"enrollment":4190,"conditions":4191,"interventions":4193},"NCT00558376","Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy",[93],"2009-03","2008-01",23,[4192],"Colonoscopy",[4170,4194],"Sodium phosphate",{"intervention":4194,"totalTrials":97,"cells":4196},{"EARLY_PHASE1":4197,"PHASE1":4199,"PHASE2":4201,"PHASE3":4203,"PHASE4":4205,"NA":4207},{"trials":4198,"activeCount":101},[],{"trials":4200,"activeCount":101},[],{"trials":4202,"activeCount":101},[],{"trials":4204,"activeCount":101},[],{"trials":4206,"activeCount":101},[],{"trials":4208,"activeCount":101},[4209],{"nctId":4185,"briefTitle":4186,"status":762,"phases":4210,"primaryCompletion":4188,"completion":4188,"start":4189,"enrollment":4190,"conditions":4211,"interventions":4212},[93],[4192],[4170,4194],{"intervention":4214,"totalTrials":97,"cells":4215},"Khat leaves",{"EARLY_PHASE1":4216,"PHASE1":4218,"PHASE2":4220,"PHASE3":4222,"PHASE4":4224,"NA":4226},{"trials":4217,"activeCount":101},[],{"trials":4219,"activeCount":101},[],{"trials":4221,"activeCount":101},[],{"trials":4223,"activeCount":101},[],{"trials":4225,"activeCount":101},[],{"trials":4227,"activeCount":101},[4228],{"nctId":4229,"briefTitle":4230,"status":208,"phases":4231,"primaryCompletion":4232,"completion":4233,"start":4234,"enrollment":2241,"conditions":4235,"interventions":4241},"NCT03917641","Effectiveness of Khat on Eyelid Wound Healing After Oculoplastic Surgery - a Prospective Study.",[93],"2020-07-01","2021-07-01","2019-07-01",[4236,4237,4238,4239,4240],"Hematoma","Surgical Wound","Surgery","Eye Bruise","Edema",[4214],{"intervention":4243,"totalTrials":97,"cells":4244},"Methylphenidate- Ritalin IR",{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4246,"activeCount":101},[],{"trials":4248,"activeCount":101},[],{"trials":4250,"activeCount":101},[],{"trials":4252,"activeCount":101},[],{"trials":4254,"activeCount":101},[],{"trials":4256,"activeCount":101},[4257],{"nctId":4258,"briefTitle":4259,"status":607,"phases":4260,"primaryCompletion":4261,"completion":4261,"start":641,"enrollment":8,"conditions":4262,"interventions":4267},"NCT01554046","The Effect of Methylphenidate Treatment in Familial Attention Deficit\u002FHyperactivity Disorder (ADHD)",[93],"2014-04",[4263,4264,4265,4266],"Attention Deficit\u002FHyperactivity Disorder Combined Type","ADHD Predominantly Inattentive Type","ADHD Predominantly Hyperactivity Type","ADHD-not Other Specified",[4243],{"intervention":4269,"totalTrials":97,"cells":4270},"Ivermectin Oral Product",{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4275,"PHASE3":4277,"PHASE4":4279,"NA":4281},{"trials":4272,"activeCount":101},[],{"trials":4274,"activeCount":101},[],{"trials":4276,"activeCount":101},[],{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"trials":4282,"activeCount":101},[4283],{"nctId":4284,"briefTitle":4285,"status":208,"phases":4286,"primaryCompletion":4287,"completion":4288,"start":3419,"enrollment":1079,"conditions":4289,"interventions":4290},"NCT04429711","Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19",[93],"2020-09-30","2020-10-31",[3251],[4269],{"intervention":4292,"totalTrials":97,"cells":4293},"Blood tests",{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4300,"PHASE4":4302,"NA":4304},{"trials":4295,"activeCount":101},[],{"trials":4297,"activeCount":101},[],{"trials":4299,"activeCount":101},[],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"trials":4305,"activeCount":101},[4306],{"nctId":4307,"briefTitle":4308,"status":208,"phases":4309,"primaryCompletion":4310,"completion":1247,"start":4311,"enrollment":4312,"conditions":4313,"interventions":4315},"NCT01613898","Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis",[],"2013-05","2010-08",17,[4314],"Cerebrotendinous Xanthomatosis (CTX)",[4292],{"intervention":4317,"totalTrials":97,"cells":4318},"Nicotine",{"EARLY_PHASE1":4319,"PHASE1":4321,"PHASE2":4323,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4320,"activeCount":101},[],{"trials":4322,"activeCount":101},[],{"trials":4324,"activeCount":101},[],{"trials":4326,"activeCount":101},[],{"trials":4328,"activeCount":101},[],{"trials":4330,"activeCount":101},[4331],{"nctId":4332,"briefTitle":4333,"status":607,"phases":4334,"primaryCompletion":1429,"completion":4335,"start":2009,"enrollment":4336,"conditions":4337,"interventions":4339},"NCT01596556","The Effect of Smoking on Thermoregulation",[93],"2014-05",16,[4338],"Cigarette Smoking",[4317],{"intervention":4341,"totalTrials":97,"cells":4342},"nitrate patch",{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4344,"activeCount":101},[],{"trials":4346,"activeCount":101},[],{"trials":4348,"activeCount":101},[],{"trials":4350,"activeCount":101},[],{"trials":4352,"activeCount":101},[],{"trials":4354,"activeCount":101},[4355],{"nctId":4356,"briefTitle":4357,"status":762,"phases":4358,"primaryCompletion":4359,"completion":4359,"start":1272,"enrollment":444,"conditions":4360,"interventions":4362},"NCT01979666","Nitrate Patch Use as Treatment of Knee AVN",[93],"2019-01",[4361],"Necrosis, Avascular, of Bone",[4341],{"intervention":4364,"totalTrials":97,"cells":4365},"Ranibizumab",{"EARLY_PHASE1":4366,"PHASE1":4368,"PHASE2":4370,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4367,"activeCount":101},[],{"trials":4369,"activeCount":101},[],{"trials":4371,"activeCount":101},[],{"trials":4373,"activeCount":101},[],{"trials":4375,"activeCount":101},[],{"trials":4377,"activeCount":101},[4378],{"nctId":4379,"briefTitle":4380,"status":208,"phases":4381,"primaryCompletion":2192,"completion":4382,"start":4383,"enrollment":531,"conditions":4384,"interventions":4386},"NCT00640640","The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)",[93],"2009-02","2007-08",[4385],"Neovascular Age Related Macular Degeneration",[4364,4387],"Bevacizumab",{"intervention":4387,"totalTrials":97,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4391,"activeCount":101},[],{"trials":4393,"activeCount":101},[],{"trials":4395,"activeCount":101},[],{"trials":4397,"activeCount":101},[],{"trials":4399,"activeCount":101},[],{"trials":4401,"activeCount":101},[4402],{"nctId":4379,"briefTitle":4380,"status":208,"phases":4403,"primaryCompletion":2192,"completion":4382,"start":4383,"enrollment":531,"conditions":4404,"interventions":4405},[93],[4385],[4364,4387],{"intervention":4407,"totalTrials":97,"cells":4408},"SARS-CoV-2 virus vaccines",{"EARLY_PHASE1":4409,"PHASE1":4411,"PHASE2":4413,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4410,"activeCount":101},[],{"trials":4412,"activeCount":101},[],{"trials":4414,"activeCount":101},[],{"trials":4416,"activeCount":101},[],{"trials":4418,"activeCount":101},[],{"trials":4420,"activeCount":101},[4421],{"nctId":4422,"briefTitle":4423,"status":607,"phases":4424,"primaryCompletion":3418,"completion":3418,"start":2750,"enrollment":2099,"conditions":4425,"interventions":4428},"NCT04748172","COVID-19 Vaccine and Ovarian Reserve",[],[4426,4427],"Fertility Issues","Vaccine Adverse Reaction",[4407],{"intervention":4430,"totalTrials":97,"cells":4431},"Tamsulosin",{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4442},{"trials":4433,"activeCount":101},[],{"trials":4435,"activeCount":101},[],{"trials":4437,"activeCount":101},[],{"trials":4439,"activeCount":101},[],{"trials":4441,"activeCount":101},[],{"trials":4443,"activeCount":101},[4444],{"nctId":4445,"briefTitle":4446,"status":208,"phases":4447,"primaryCompletion":4448,"completion":4449,"start":4450,"enrollment":469,"conditions":4451,"interventions":4453},"NCT04359979","Tamsulosin for Thyroid Lid Retraction",[93],"2023-05-01","2023-12-01","2020-05-01",[190,4452],"Eyelid Diseases",[4430],{"intervention":4455,"totalTrials":97,"cells":4456},"povidone-iodine 4%",{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4463,"PHASE4":4465,"NA":4467},{"trials":4458,"activeCount":101},[],{"trials":4460,"activeCount":101},[],{"trials":4462,"activeCount":101},[],{"trials":4464,"activeCount":101},[],{"trials":4466,"activeCount":101},[],{"trials":4468,"activeCount":101},[4469],{"nctId":4470,"briefTitle":4471,"status":208,"phases":4472,"primaryCompletion":4473,"completion":4103,"start":3333,"enrollment":469,"conditions":4474,"interventions":4477},"NCT02337972","Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients",[93],"2015-12",[4475,4476],"Diabetic Retinopathy","Diabetic Macular Edema",[4455],{"intervention":4479,"totalTrials":97,"cells":4480},"Dexamethasone Disodium Phosphate 0.1%",{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4487,"PHASE4":4489,"NA":4491},{"trials":4482,"activeCount":101},[],{"trials":4484,"activeCount":101},[],{"trials":4486,"activeCount":101},[],{"trials":4488,"activeCount":101},[],{"trials":4490,"activeCount":101},[],{"trials":4492,"activeCount":101},[4493],{"nctId":4494,"briefTitle":4495,"status":208,"phases":4496,"primaryCompletion":3622,"completion":1516,"start":4497,"enrollment":1079,"conditions":4498,"interventions":4502},"NCT02955641","Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy",[93],"2016-11-01",[4499,4500,4501],"Glaucoma, Closed-Angle","Glaucoma, Narrow-Angle","Glaucoma, Angle-Closure",[4479,4503,4504],"Nepafenac 0.1%","Hydroxyethylcellulose 0.19%",{"intervention":4503,"totalTrials":97,"cells":4506},{"EARLY_PHASE1":4507,"PHASE1":4509,"PHASE2":4511,"PHASE3":4513,"PHASE4":4515,"NA":4517},{"trials":4508,"activeCount":101},[],{"trials":4510,"activeCount":101},[],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[],{"trials":4516,"activeCount":101},[],{"trials":4518,"activeCount":101},[4519],{"nctId":4494,"briefTitle":4495,"status":208,"phases":4520,"primaryCompletion":3622,"completion":1516,"start":4497,"enrollment":1079,"conditions":4521,"interventions":4522},[93],[4499,4500,4501],[4479,4503,4504],{"intervention":4504,"totalTrials":97,"cells":4524},{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4529,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4526,"activeCount":101},[],{"trials":4528,"activeCount":101},[],{"trials":4530,"activeCount":101},[],{"trials":4532,"activeCount":101},[],{"trials":4534,"activeCount":101},[],{"trials":4536,"activeCount":101},[4537],{"nctId":4494,"briefTitle":4495,"status":208,"phases":4538,"primaryCompletion":3622,"completion":1516,"start":4497,"enrollment":1079,"conditions":4539,"interventions":4540},[93],[4499,4500,4501],[4479,4503,4504],{"intervention":4542,"totalTrials":97,"cells":4543},"Rofecoxib",{"EARLY_PHASE1":4544,"PHASE1":4546,"PHASE2":4548,"PHASE3":4550,"PHASE4":4552,"NA":4554},{"trials":4545,"activeCount":101},[],{"trials":4547,"activeCount":101},[],{"trials":4549,"activeCount":101},[],{"trials":4551,"activeCount":101},[],{"trials":4553,"activeCount":101},[],{"trials":4555,"activeCount":101},[4556],{"nctId":4557,"briefTitle":4558,"status":607,"phases":4559,"completion":4560,"start":986,"enrollment":4561,"conditions":4562,"interventions":4564},"NCT00263094","An End to the Yom Kippur (and Ramadan) Headache",[93],"2004-11",220,[4563],"Headache",[4542],{"intervention":4566,"totalTrials":97,"cells":4567},"COVID-19 vaccination",{"EARLY_PHASE1":4568,"PHASE1":4570,"PHASE2":4572,"PHASE3":4574,"PHASE4":4576,"NA":4578},{"trials":4569,"activeCount":101},[],{"trials":4571,"activeCount":101},[],{"trials":4573,"activeCount":101},[],{"trials":4575,"activeCount":101},[],{"trials":4577,"activeCount":101},[],{"trials":4579,"activeCount":101},[4580],{"nctId":4581,"briefTitle":4582,"status":208,"phases":4583,"primaryCompletion":4584,"completion":4585,"start":4586,"enrollment":4587,"conditions":4588,"interventions":4589},"NCT05075499","Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab",[93],"2021-12","2022-09","2021-03-20",70,[24],[4566],{"intervention":4591,"totalTrials":97,"cells":4592},"diclofenac drops",{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4597,"PHASE3":4599,"PHASE4":4601,"NA":4603},{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[],{"trials":4602,"activeCount":101},[],{"trials":4604,"activeCount":101},[4605],{"nctId":4606,"briefTitle":4607,"status":607,"phases":4608,"primaryCompletion":4189,"completion":4189,"start":4609,"enrollment":469,"conditions":4610,"interventions":4613},"NCT00825864","Diclofenac vs Dexamethasone in Combined Surgery",[93],"2004-01",[4611,4612],"Glaucoma","Cataract",[4591,4614],"dexamethasone sodium phosphate 0.1% eye drops",{"intervention":4614,"totalTrials":97,"cells":4616},{"EARLY_PHASE1":4617,"PHASE1":4619,"PHASE2":4621,"PHASE3":4623,"PHASE4":4625,"NA":4627},{"trials":4618,"activeCount":101},[],{"trials":4620,"activeCount":101},[],{"trials":4622,"activeCount":101},[],{"trials":4624,"activeCount":101},[],{"trials":4626,"activeCount":101},[],{"trials":4628,"activeCount":101},[4629],{"nctId":4606,"briefTitle":4607,"status":607,"phases":4630,"primaryCompletion":4189,"completion":4189,"start":4609,"enrollment":469,"conditions":4631,"interventions":4632},[93],[4611,4612],[4591,4614],{"intervention":4634,"totalTrials":97,"cells":4635},"Pentostam",{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4640,"PHASE3":4642,"PHASE4":4644,"NA":4646},{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[],{"trials":4643,"activeCount":101},[],{"trials":4645,"activeCount":101},[],{"trials":4647,"activeCount":101},[4648],{"nctId":4649,"briefTitle":4650,"status":208,"phases":4651,"primaryCompletion":3561,"completion":227,"start":1540,"enrollment":1079,"conditions":4652,"interventions":4654},"NCT02281669","Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients",[],[4653],"Cutaneous Leishmaniasis",[4634],{"intervention":4656,"totalTrials":97,"cells":4657},"Lorazepam",{"EARLY_PHASE1":4658,"PHASE1":4660,"PHASE2":4662,"PHASE3":4664,"PHASE4":4666,"NA":4668},{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":101},[],{"trials":4663,"activeCount":101},[],{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":101},[],{"trials":4669,"activeCount":101},[4670],{"nctId":4671,"briefTitle":4672,"status":208,"phases":4673,"primaryCompletion":211,"start":4674,"enrollment":4587,"conditions":4675,"interventions":4678},"NCT01684085","Explanation About Sleep in Post Trauma Patients",[93],"2012-10",[4676,4677],"Post Traumatic Stress Disorder","Sleep Deprivation",[4656],{"intervention":4680,"totalTrials":97,"cells":4681},"Efrin drops",{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4686,"PHASE3":4688,"PHASE4":4690,"NA":4692},{"trials":4683,"activeCount":101},[],{"trials":4685,"activeCount":101},[],{"trials":4687,"activeCount":101},[],{"trials":4689,"activeCount":101},[],{"trials":4691,"activeCount":101},[],{"trials":4693,"activeCount":101},[4694],{"nctId":4695,"briefTitle":4696,"status":208,"phases":4697,"primaryCompletion":4698,"completion":4699,"start":4700,"enrollment":4587,"conditions":4701,"interventions":4703},"NCT04150588","The Correlation Between MMCR and Phenylephrine Test",[],"2021-11-30","2022-11-30","2019-11-30",[4702],"the Correlation Between Erin Test and Müller's Muscle-Conjunctival Resection",[4680],{"intervention":4158,"totalTrials":97,"cells":4705},{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4712,"PHASE4":4714,"NA":4716},{"trials":4707,"activeCount":101},[],{"trials":4709,"activeCount":101},[],{"trials":4711,"activeCount":101},[],{"trials":4713,"activeCount":101},[],{"trials":4715,"activeCount":101},[],{"trials":4717,"activeCount":101},[4718],{"nctId":4152,"briefTitle":4153,"status":208,"phases":4719,"primaryCompletion":610,"completion":610,"start":1272,"enrollment":531,"conditions":4720,"interventions":4721},[93],[4156],[4158,4137],{"intervention":4723,"totalTrials":97,"cells":4724},"PCV",{"EARLY_PHASE1":4725,"PHASE1":4727,"PHASE2":4729,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4726,"activeCount":101},[],{"trials":4728,"activeCount":101},[],{"trials":4730,"activeCount":101},[],{"trials":4732,"activeCount":101},[],{"trials":4734,"activeCount":101},[],{"trials":4736,"activeCount":101},[4737],{"nctId":4738,"briefTitle":4739,"status":208,"phases":4740,"primaryCompletion":4741,"completion":3812,"start":4261,"enrollment":4742,"conditions":4743,"interventions":4745},"NCT03064620","PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study",[],"2020-08",12800,[4744],"Streptococcus Pneumoniae",[4723],{"intervention":4747,"totalTrials":97,"cells":4748},"erythropoietin and early iron supplements",{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4753,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4750,"activeCount":101},[],{"trials":4752,"activeCount":101},[],{"trials":4754,"activeCount":101},[],{"trials":4756,"activeCount":101},[],{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[4761],{"nctId":4762,"briefTitle":4763,"status":208,"phases":4764,"completion":2289,"start":4765,"enrollment":2012,"conditions":4766,"interventions":4768},"NCT00339001","Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity",[],"2006-04",[4767],"Retinopathy of Prematurity",[4747],{"intervention":4770,"totalTrials":97,"cells":4771},"Paracetamol",{"EARLY_PHASE1":4772,"PHASE1":4774,"PHASE2":4776,"PHASE3":4778,"PHASE4":4780,"NA":4782},{"trials":4773,"activeCount":101},[],{"trials":4775,"activeCount":101},[],{"trials":4777,"activeCount":101},[],{"trials":4779,"activeCount":101},[],{"trials":4781,"activeCount":101},[],{"trials":4783,"activeCount":101},[4784],{"nctId":4785,"briefTitle":4786,"status":208,"phases":4787,"primaryCompletion":656,"start":1166,"enrollment":469,"conditions":4788,"interventions":4791},"NCT02539979","A Trial of Intravenous Paracetamol vs. Placebo in Patients Receiving Radiofrequency Ablation of the Medial Branch Facet Nerve",[93],[4789,4790],"Chronic Lower Back Pain","Lumbar Facet Syndrome",[4770],{"intervention":4793,"totalTrials":97,"cells":4794},"Prevenar®",{"EARLY_PHASE1":4795,"PHASE1":4797,"PHASE2":4799,"PHASE3":4801,"PHASE4":4803,"NA":4805},{"trials":4796,"activeCount":101},[],{"trials":4798,"activeCount":101},[],{"trials":4800,"activeCount":101},[],{"trials":4802,"activeCount":101},[],{"trials":4804,"activeCount":101},[],{"trials":4806,"activeCount":101},[4807],{"nctId":4808,"briefTitle":4809,"status":208,"phases":4810,"primaryCompletion":4811,"completion":4811,"start":1010,"enrollment":642,"conditions":4812,"interventions":4814},"NCT01075438","Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients",[],"2011-02",[4813],"Ataxia Telangiectasia",[4793,4815],"Pneumovax®",{"intervention":4815,"totalTrials":97,"cells":4817},{"EARLY_PHASE1":4818,"PHASE1":4820,"PHASE2":4822,"PHASE3":4824,"PHASE4":4826,"NA":4828},{"trials":4819,"activeCount":101},[],{"trials":4821,"activeCount":101},[],{"trials":4823,"activeCount":101},[],{"trials":4825,"activeCount":101},[],{"trials":4827,"activeCount":101},[],{"trials":4829,"activeCount":101},[4830],{"nctId":4808,"briefTitle":4809,"status":208,"phases":4831,"primaryCompletion":4811,"completion":4811,"start":1010,"enrollment":642,"conditions":4832,"interventions":4833},[],[4813],[4793,4815],{"intervention":4835,"totalTrials":97,"cells":4836},"Varenicline",{"EARLY_PHASE1":4837,"PHASE1":4839,"PHASE2":4841,"PHASE3":4843,"PHASE4":4845,"NA":4847},{"trials":4838,"activeCount":101},[],{"trials":4840,"activeCount":101},[],{"trials":4842,"activeCount":101},[],{"trials":4844,"activeCount":101},[],{"trials":4846,"activeCount":101},[],{"trials":4848,"activeCount":101},[4849],{"nctId":4850,"briefTitle":4851,"status":208,"phases":4852,"primaryCompletion":4853,"completion":226,"start":656,"enrollment":3562,"conditions":4854,"interventions":4856},"NCT02106637","Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS",[93],"2018-08",[1249,4855],"Smoking Cessation",[4835],{"intervention":4168,"totalTrials":97,"cells":4858},{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":101},[],{"trials":4864,"activeCount":101},[],{"trials":4866,"activeCount":101},[],{"trials":4868,"activeCount":101},[],{"trials":4870,"activeCount":101},[4871],{"nctId":4160,"briefTitle":4161,"status":607,"phases":4872,"primaryCompletion":4163,"completion":4163,"start":4164,"enrollment":2099,"conditions":4873,"interventions":4874},[93],[4166],[4168,4137],{"intervention":4876,"totalTrials":97,"cells":4877},"Infliximab",{"EARLY_PHASE1":4878,"PHASE1":4880,"PHASE2":4882,"PHASE3":4884,"PHASE4":4886,"NA":4888},{"trials":4879,"activeCount":101},[],{"trials":4881,"activeCount":101},[],{"trials":4883,"activeCount":101},[],{"trials":4885,"activeCount":101},[],{"trials":4887,"activeCount":101},[],{"trials":4889,"activeCount":101},[4890],{"nctId":4891,"briefTitle":4892,"status":762,"phases":4893,"conditions":4894,"interventions":4896},"NCT00252369","Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.",[93],[4895],"Crohn's Disease",[4876],{"intervention":4898,"totalTrials":97,"cells":4899},"Eltroxin",{"EARLY_PHASE1":4900,"PHASE1":4902,"PHASE2":4904,"PHASE3":4906,"PHASE4":4908,"NA":4910},{"trials":4901,"activeCount":101},[],{"trials":4903,"activeCount":101},[],{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[],{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[4912],{"nctId":4913,"briefTitle":4914,"status":208,"phases":4915,"primaryCompletion":3334,"completion":3465,"start":4811,"enrollment":469,"conditions":4916,"interventions":4918},"NCT01280292","Central Hypothyroidism, a Novel Laboratory Measurement",[93],[4917],"Central Hypothyroidism",[4898],{"intervention":4920,"totalTrials":97,"cells":4921},"Ziprasidone",{"EARLY_PHASE1":4922,"PHASE1":4924,"PHASE2":4926,"PHASE3":4928,"PHASE4":4930,"NA":4932},{"trials":4923,"activeCount":101},[],{"trials":4925,"activeCount":101},[],{"trials":4927,"activeCount":101},[],{"trials":4929,"activeCount":101},[],{"trials":4931,"activeCount":101},[],{"trials":4933,"activeCount":101},[4934],{"nctId":4935,"briefTitle":4936,"status":607,"phases":4937,"primaryCompletion":3200,"completion":4938,"start":3837,"enrollment":4939,"conditions":4940,"interventions":4942},"NCT00229385","Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)",[93],"2010-04",45,[15,4941],"Obsessive Compulsive Disorder",[4920],{"intervention":4944,"totalTrials":97,"cells":4945},"Noninvasive core temperature thermistor",{"EARLY_PHASE1":4946,"PHASE1":4948,"PHASE2":4950,"PHASE3":4952,"PHASE4":4954,"NA":4956},{"trials":4947,"activeCount":101},[],{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[],{"trials":4953,"activeCount":101},[],{"trials":4955,"activeCount":101},[],{"trials":4957,"activeCount":101},[4958],{"nctId":4959,"briefTitle":4960,"status":208,"phases":4961,"primaryCompletion":1165,"start":1429,"enrollment":3888,"conditions":4962,"interventions":4964},"NCT02017184","Non-invasive Sensor for Core Temperature Measurement",[93],[4963],"Body Temperature Regulation",[4944],{"intervention":4966,"totalTrials":97,"cells":4967},"Letrozole, Gonadotropins",{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4972,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4969,"activeCount":101},[],{"trials":4971,"activeCount":101},[],{"trials":4973,"activeCount":101},[],{"trials":4975,"activeCount":101},[],{"trials":4977,"activeCount":101},[],{"trials":4979,"activeCount":101},[4980],{"nctId":4981,"briefTitle":4982,"status":208,"phases":4983,"primaryCompletion":696,"completion":696,"start":4984,"enrollment":2099,"conditions":4985,"interventions":4987},"NCT02128360","Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve",[93],"2015-03",[4986],"Infertility",[4966,4988],"Gonadotropins",{"intervention":4988,"totalTrials":97,"cells":4990},{"EARLY_PHASE1":4991,"PHASE1":4993,"PHASE2":4995,"PHASE3":4997,"PHASE4":4999,"NA":5001},{"trials":4992,"activeCount":101},[],{"trials":4994,"activeCount":101},[],{"trials":4996,"activeCount":101},[],{"trials":4998,"activeCount":101},[],{"trials":5000,"activeCount":101},[],{"trials":5002,"activeCount":101},[5003],{"nctId":4981,"briefTitle":4982,"status":208,"phases":5004,"primaryCompletion":696,"completion":696,"start":4984,"enrollment":2099,"conditions":5005,"interventions":5006},[93],[4986],[4966,4988],{"intervention":5008,"totalTrials":97,"cells":5009},"Astaxanthin",{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5011,"activeCount":101},[],{"trials":5013,"activeCount":101},[],{"trials":5015,"activeCount":101},[],{"trials":5017,"activeCount":101},[],{"trials":5019,"activeCount":101},[],{"trials":5021,"activeCount":101},[5022],{"nctId":5023,"briefTitle":5024,"status":208,"phases":5025,"primaryCompletion":1122,"completion":1166,"start":4335,"enrollment":5026,"conditions":5027,"interventions":5028},"NCT02088242","Physiological and Molecular Influences of Astaxanthin Supplementation on Heat Strain in Humans",[93],34,[4963],[5008],{"intervention":5030,"totalTrials":97,"cells":5031},"Tadalafil and acetazolamide",{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5038,"PHASE4":5040,"NA":5042},{"trials":5033,"activeCount":101},[],{"trials":5035,"activeCount":101},[],{"trials":5037,"activeCount":101},[],{"trials":5039,"activeCount":101},[],{"trials":5041,"activeCount":101},[],{"trials":5043,"activeCount":101},[5044],{"nctId":5045,"briefTitle":5046,"status":607,"phases":5047,"primaryCompletion":4311,"completion":4311,"start":3837,"enrollment":5048,"conditions":5049,"interventions":5052},"NCT01060969","Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention",[93],55,[5050,5051],"Pulmonary Edema","Cerebral Edema",[5030,5053],"Acetazolamide",{"intervention":5053,"totalTrials":97,"cells":5055},{"EARLY_PHASE1":5056,"PHASE1":5058,"PHASE2":5060,"PHASE3":5062,"PHASE4":5064,"NA":5066},{"trials":5057,"activeCount":101},[],{"trials":5059,"activeCount":101},[],{"trials":5061,"activeCount":101},[],{"trials":5063,"activeCount":101},[],{"trials":5065,"activeCount":101},[],{"trials":5067,"activeCount":101},[5068],{"nctId":5045,"briefTitle":5046,"status":607,"phases":5069,"primaryCompletion":4311,"completion":4311,"start":3837,"enrollment":5048,"conditions":5070,"interventions":5071},[93],[5050,5051],[5030,5053],{"intervention":5073,"totalTrials":97,"cells":5074},"Celecoxib",{"EARLY_PHASE1":5075,"PHASE1":5077,"PHASE2":5079,"PHASE3":5081,"PHASE4":5083,"NA":5085},{"trials":5076,"activeCount":101},[],{"trials":5078,"activeCount":101},[],{"trials":5080,"activeCount":101},[],{"trials":5082,"activeCount":101},[],{"trials":5084,"activeCount":101},[],{"trials":5086,"activeCount":101},[5087],{"nctId":5088,"briefTitle":5089,"status":208,"phases":5090,"primaryCompletion":226,"start":696,"enrollment":1079,"conditions":5091,"interventions":5093},"NCT02790203","Perioperative Use of a Selective COX2 Inhibitor in Patients Undergoing Elective Colorectal Surgery: the Effect on Post-operative Bowel Motility and Post-operative Pain",[93],[5092],"Prevention of Post Operative Ileus",[5073],{"intervention":5095,"totalTrials":97,"cells":5096},"IOP reduction of Brimonidine and Timolol with time interval",{"EARLY_PHASE1":5097,"PHASE1":5099,"PHASE2":5101,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5098,"activeCount":101},[],{"trials":5100,"activeCount":101},[],{"trials":5102,"activeCount":101},[],{"trials":5104,"activeCount":101},[],{"trials":5106,"activeCount":101},[],{"trials":5108,"activeCount":101},[5109],{"nctId":5110,"briefTitle":5111,"status":208,"phases":5112,"primaryCompletion":5113,"completion":5113,"start":5114,"enrollment":5115,"conditions":5116,"interventions":5118},"NCT03220490","Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops",[93],"2022-11-01","2017-11-01",65,[4611,5117],"Glaucoma; Drugs",[5095,5119],"IOP reduction of Brimonidine and Timolol no time interval",{"intervention":5119,"totalTrials":97,"cells":5121},{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5128,"PHASE4":5130,"NA":5132},{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":101},[],{"trials":5127,"activeCount":101},[],{"trials":5129,"activeCount":101},[],{"trials":5131,"activeCount":101},[],{"trials":5133,"activeCount":101},[5134],{"nctId":5110,"briefTitle":5111,"status":208,"phases":5135,"primaryCompletion":5113,"completion":5113,"start":5114,"enrollment":5115,"conditions":5136,"interventions":5137},[93],[4611,5117],[5095,5119],{"intervention":5139,"totalTrials":97,"cells":5140},"Oxytocin IV",{"EARLY_PHASE1":5141,"PHASE1":5143,"PHASE2":5145,"PHASE3":5147,"PHASE4":5149,"NA":5151},{"trials":5142,"activeCount":101},[],{"trials":5144,"activeCount":101},[],{"trials":5146,"activeCount":101},[],{"trials":5148,"activeCount":101},[],{"trials":5150,"activeCount":101},[],{"trials":5152,"activeCount":101},[5153],{"nctId":5154,"briefTitle":5155,"status":208,"phases":5156,"primaryCompletion":718,"completion":718,"start":5157,"enrollment":164,"conditions":5158,"interventions":5160},"NCT00684606","Transcervical Foley Catheter With or Without Oxytocin for Induction of Labor",[93],"2008-05",[32,5159],"Induction of Labor",[5139],{"intervention":5162,"totalTrials":97,"cells":5163},"atorvastatin",{"EARLY_PHASE1":5164,"PHASE1":5166,"PHASE2":5168,"PHASE3":5170,"PHASE4":5172,"NA":5174},{"trials":5165,"activeCount":101},[],{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[],{"trials":5171,"activeCount":101},[],{"trials":5173,"activeCount":101},[],{"trials":5175,"activeCount":101},[5176],{"nctId":5177,"briefTitle":5178,"status":794,"phases":5179,"primaryCompletion":4473,"completion":4473,"start":4473,"enrollment":101,"conditions":5180,"interventions":5182},"NCT01987310","Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment",[93],[5181],"Non Alcoholic Fatty Liver Disease",[5162],{"intervention":5184,"totalTrials":97,"cells":5185},"Medical Cannabis",{"EARLY_PHASE1":5186,"PHASE1":5188,"PHASE2":5190,"PHASE3":5192,"PHASE4":5194,"NA":5196},{"trials":5187,"activeCount":101},[],{"trials":5189,"activeCount":101},[],{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[],{"trials":5195,"activeCount":101},[],{"trials":5197,"activeCount":101},[5198],{"nctId":5199,"briefTitle":5200,"status":208,"phases":5201,"primaryCompletion":5202,"completion":5203,"start":5204,"enrollment":1079,"conditions":5205,"interventions":5208},"NCT05106504","Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease",[],"2023-08","2024-08","2021-09-02",[5206,5207],"Bladder, Overactive","Parkinson Disease",[5184],{"intervention":5210,"totalTrials":97,"cells":5211},"GnRH agonist 0.2 mg + hCG 250 mcg",{"EARLY_PHASE1":5212,"PHASE1":5214,"PHASE2":5216,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5213,"activeCount":101},[],{"trials":5215,"activeCount":101},[],{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[],{"trials":5221,"activeCount":101},[],{"trials":5223,"activeCount":101},[5224],{"nctId":5225,"briefTitle":5226,"status":607,"phases":5227,"primaryCompletion":5228,"completion":5228,"start":5229,"enrollment":1079,"conditions":5230,"interventions":5231},"NCT02368964","IVF Treatment in Women With Immature Oocytes in Previous Cycle",[93],"2020-06-01","2015-02-01",[4986],[5210,5232],"high dose hCG 500 mcg",{"intervention":5232,"totalTrials":97,"cells":5234},{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5239,"PHASE3":5241,"PHASE4":5243,"NA":5245},{"trials":5236,"activeCount":101},[],{"trials":5238,"activeCount":101},[],{"trials":5240,"activeCount":101},[],{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[],{"trials":5246,"activeCount":101},[5247],{"nctId":5225,"briefTitle":5226,"status":607,"phases":5248,"primaryCompletion":5228,"completion":5228,"start":5229,"enrollment":1079,"conditions":5249,"interventions":5250},[93],[4986],[5210,5232],{"intervention":5252,"totalTrials":97,"cells":5253},"Blood sample",{"EARLY_PHASE1":5254,"PHASE1":5256,"PHASE2":5258,"PHASE3":5260,"PHASE4":5262,"NA":5264},{"trials":5255,"activeCount":101},[],{"trials":5257,"activeCount":101},[],{"trials":5259,"activeCount":101},[],{"trials":5261,"activeCount":101},[],{"trials":5263,"activeCount":101},[],{"trials":5265,"activeCount":101},[5266],{"nctId":5267,"briefTitle":5268,"status":607,"phases":5269,"primaryCompletion":5270,"completion":5270,"start":919,"enrollment":5271,"conditions":5272,"interventions":5274},"NCT02821702","Fertility Post Placenta Accrete",[93],"2019-12",135,[5273],"Fertility",[5252],{"intervention":5276,"totalTrials":97,"cells":5277},"Tinidazole and Albendazole",{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5284,"PHASE4":5286,"NA":5288},{"trials":5279,"activeCount":101},[],{"trials":5281,"activeCount":101},[],{"trials":5283,"activeCount":101},[],{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"trials":5289,"activeCount":101},[5290],{"nctId":5291,"briefTitle":5292,"status":208,"phases":5293,"primaryCompletion":4473,"completion":1078,"start":2021,"enrollment":1079,"conditions":5294,"interventions":5298},"NCT01070277","Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea",[93],[5295,5296,5297],"Chronic Diarrhea","Abdominal Pain","Bloating",[5276],{"intervention":5300,"totalTrials":97,"cells":5301},"multiple doses of sucrose",{"EARLY_PHASE1":5302,"PHASE1":5304,"PHASE2":5306,"PHASE3":5308,"PHASE4":5310,"NA":5312},{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[],{"trials":5307,"activeCount":101},[],{"trials":5309,"activeCount":101},[],{"trials":5311,"activeCount":101},[],{"trials":5313,"activeCount":101},[5314],{"nctId":5315,"briefTitle":5316,"status":208,"phases":5317,"primaryCompletion":494,"completion":1247,"start":1668,"enrollment":2569,"conditions":5318,"interventions":5320},"NCT01742520","Neurodevelopmental Outcomes of Preterm Infants Treated for Pain Management With Repeated Doses of Sucrose 24%",[93],[5319],"Development",[5300,5321],"Formula or breast milk",{"intervention":5321,"totalTrials":97,"cells":5323},{"EARLY_PHASE1":5324,"PHASE1":5326,"PHASE2":5328,"PHASE3":5330,"PHASE4":5332,"NA":5334},{"trials":5325,"activeCount":101},[],{"trials":5327,"activeCount":101},[],{"trials":5329,"activeCount":101},[],{"trials":5331,"activeCount":101},[],{"trials":5333,"activeCount":101},[],{"trials":5335,"activeCount":101},[5336],{"nctId":5315,"briefTitle":5316,"status":208,"phases":5337,"primaryCompletion":494,"completion":1247,"start":1668,"enrollment":2569,"conditions":5338,"interventions":5339},[93],[5319],[5300,5321],{"intervention":5341,"totalTrials":97,"cells":5342},"Duloxetine",{"EARLY_PHASE1":5343,"PHASE1":5345,"PHASE2":5347,"PHASE3":5349,"PHASE4":5351,"NA":5353},{"trials":5344,"activeCount":101},[],{"trials":5346,"activeCount":101},[],{"trials":5348,"activeCount":101},[],{"trials":5350,"activeCount":101},[],{"trials":5352,"activeCount":101},[],{"trials":5354,"activeCount":101},[5355],{"nctId":5356,"briefTitle":5357,"status":794,"phases":5358,"enrollment":8,"conditions":5359,"interventions":5361},"NCT00399022","Treatment With Duloxetine for OCD Patients",[93],[5360],"OCD",[5341],{"intervention":5363,"totalTrials":97,"cells":5364},"Hydrocortisone",{"EARLY_PHASE1":5365,"PHASE1":5367,"PHASE2":5369,"PHASE3":5371,"PHASE4":5373,"NA":5375},{"trials":5366,"activeCount":101},[],{"trials":5368,"activeCount":101},[],{"trials":5370,"activeCount":101},[],{"trials":5372,"activeCount":101},[],{"trials":5374,"activeCount":101},[],{"trials":5376,"activeCount":101},[5377],{"nctId":5378,"briefTitle":5379,"status":208,"phases":5380,"primaryCompletion":582,"completion":1078,"start":2728,"enrollment":164,"conditions":5381,"interventions":5382},"NCT00855270","Efficacy of Single Dose IV Hydrocortisone in Post Traumatic Stress Disorder (PTSD) Prevention",[93],[4676],[5363],{"intervention":5384,"totalTrials":97,"cells":5385},"recombinant factor VIIa",{"EARLY_PHASE1":5386,"PHASE1":5388,"PHASE2":5390,"PHASE3":5392,"PHASE4":5394,"NA":5396},{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[],{"trials":5395,"activeCount":101},[],{"trials":5397,"activeCount":101},[5398],{"nctId":5399,"briefTitle":5400,"status":208,"phases":5401,"primaryCompletion":610,"completion":610,"start":3667,"enrollment":2753,"conditions":5402,"interventions":5404},"NCT01538160","A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery",[93],[5403],"Hemophilia C",[5384],{"intervention":5406,"totalTrials":97,"cells":5407},"Naltrexone",{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5414,"PHASE4":5416,"NA":5418},{"trials":5409,"activeCount":101},[],{"trials":5411,"activeCount":101},[],{"trials":5413,"activeCount":101},[],{"trials":5415,"activeCount":101},[],{"trials":5417,"activeCount":101},[],{"trials":5419,"activeCount":101},[5420],{"nctId":5421,"briefTitle":5422,"status":607,"phases":5423,"primaryCompletion":4009,"completion":4009,"start":5424,"conditions":5425,"interventions":5426},"NCT00234689","Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients",[93],"2002-01",[4941],[5406],{"intervention":5428,"totalTrials":97,"cells":5429},"midazolam",{"EARLY_PHASE1":5430,"PHASE1":5432,"PHASE2":5434,"PHASE3":5436,"PHASE4":5438,"NA":5440},{"trials":5431,"activeCount":101},[],{"trials":5433,"activeCount":101},[],{"trials":5435,"activeCount":101},[],{"trials":5437,"activeCount":101},[],{"trials":5439,"activeCount":101},[],{"trials":5441,"activeCount":101},[5442],{"nctId":5443,"briefTitle":5444,"status":607,"phases":5445,"primaryCompletion":2438,"completion":2438,"start":3837,"enrollment":5115,"conditions":5446,"interventions":5448},"NCT00609960","Clowns as Treatment for Preoperative Anxiety in Children: A Randomized Controlled Trial",[93],[5447],"Pre Operative Anxiety",[5428],{"intervention":5450,"totalTrials":97,"cells":5451},"CYTOTEC",{"EARLY_PHASE1":5452,"PHASE1":5454,"PHASE2":5456,"PHASE3":5458,"PHASE4":5460,"NA":5462},{"trials":5453,"activeCount":101},[],{"trials":5455,"activeCount":101},[],{"trials":5457,"activeCount":101},[],{"trials":5459,"activeCount":101},[],{"trials":5461,"activeCount":101},[],{"trials":5463,"activeCount":101},[5464],{"nctId":5465,"briefTitle":5466,"status":208,"phases":5467,"primaryCompletion":3937,"completion":5468,"start":5469,"enrollment":1079,"conditions":5470,"interventions":5472},"NCT02581761","A Prospective Study of Misoprostol Administration in Asymptomatic Patients With Pregnancies of Unknown Location",[93],"2018-03","2015-11",[5471],"Pregnancies of Unknown Location (PUL)",[5450],{"intervention":5474,"totalTrials":97,"cells":5475},"Provigil",{"EARLY_PHASE1":5476,"PHASE1":5478,"PHASE2":5480,"PHASE3":5482,"PHASE4":5484,"NA":5486},{"trials":5477,"activeCount":101},[],{"trials":5479,"activeCount":101},[],{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[5488],{"nctId":5489,"briefTitle":5490,"status":208,"phases":5491,"completion":2289,"start":5492,"enrollment":469,"conditions":5493,"interventions":5495},"NCT00220506","Fatigue Treatment Using Provigil",[93],"2005-09",[5494],"All Multiple Sclerosis Patients",[5474],{"intervention":5497,"totalTrials":97,"cells":5498},"Osimertinib",{"EARLY_PHASE1":5499,"PHASE1":5501,"PHASE2":5503,"PHASE3":5505,"PHASE4":5507,"NA":5509},{"trials":5500,"activeCount":101},[],{"trials":5502,"activeCount":101},[],{"trials":5504,"activeCount":101},[],{"trials":5506,"activeCount":101},[],{"trials":5508,"activeCount":101},[],{"trials":5510,"activeCount":101},[5511],{"nctId":5512,"briefTitle":5513,"status":5514,"phases":5515,"primaryCompletion":5516,"completion":5516,"start":5517,"enrollment":1079,"conditions":5518,"interventions":5521},"NCT05421936","Osimertinib for NSCLC With Uncommon EGFR Mutations","SUSPENDED",[],"2024-09","2020-09-27",[5519,5520],"Carcinoma, Non-Small-Cell Lung","Genes, erbB-1",[5497],{"intervention":5523,"totalTrials":97,"cells":5524},"Profound neuromuscular blockade",{"EARLY_PHASE1":5525,"PHASE1":5527,"PHASE2":5529,"PHASE3":5531,"PHASE4":5533,"NA":5535},{"trials":5526,"activeCount":101},[],{"trials":5528,"activeCount":101},[],{"trials":5530,"activeCount":101},[],{"trials":5532,"activeCount":101},[],{"trials":5534,"activeCount":101},[],{"trials":5536,"activeCount":101},[5537],{"nctId":5538,"briefTitle":5539,"status":208,"phases":5540,"primaryCompletion":5541,"completion":5541,"start":5542,"enrollment":8,"conditions":5543,"interventions":5545},"NCT01564576","Neuromuscular Blockade and Surgical Conditions",[93],"2012-08","2012-04",[5544],"Morbid Obesity",[5523]]